YOU GIVE

WE ACT

LIVES SAVED
YOU GIVE. WE ACT. LIVES SAVED. IN ESSENCE, THIS IS HOW WE GET TO SOMEDAY—THE DAY WHEN CANCER IS NO LONGER PART OF OUR LIVES. AND WE’RE WELL ON OUR WAY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) HAS INVESTED MORE THAN $1 BILLION TO ACCELERATE INNOVATIVE, LIFE-SAVING TREATMENTS THAT ONCE WERE BEYOND OUR IMAGINATION. OUR CURES AND ACCESS AGENDA IMPACTS THE CANCER LANDSCAPE. THE END IS CLOSER WHEN ALL OF US CONCENTRATE OUR FUNDS AND EFFORTS THROUGH LLS. SOMEDAY BECOMES TODAY WHEN WE EACH DECLARE: CANCER ENDS WITH ME.

THE HARRY T. MANGURIAN, JR. FOUNDATION GAVE $4MM TO SUPPORT LLS’S BEAT AML INITIATIVE.

LLS COMMITTED $79.8MM TO RESEARCH IN FISCAL YEAR 2014.

THE U.S. FOOD & DRUG ADMINISTRATION APPROVED THE FIRST BREAKTHROUGH THERAPY-DESIGNATED TREATMENTS FOR BLOOD CANCER PATIENTS.
LLS supported 350+ blood cancer research projects worldwide.

The #1 national corporate partner for Light the Night, Burlington raised $3MM+.

LLS launched Beat AML, a collaboration with Oregon Health & Science University to identify genes that cause AML, and work with biopharmaceutical companies to test new agents that target those genes alone or in combination to personalize therapy for patients.

“My name is Rhett, and cancer ends with me! Cancer cells are the bad guys. For three and a half years, I took chemo to get the bad guys out.” Rhett Krawitt, survivor.

More than 1.1 million people in the U.S. are living with, or are in remission from, a blood cancer.

The #1 national corporate partner for Light the Night, Burlington raised $3MM+.
LLS announced 14 Quest for Cures research grants to provide funding for unmet medical need, and to identify why some treatments are not successful for certain patients.

In 1964, the five-year survival rate for the most commonly diagnosed leukemia among children was 3%. Today it’s 90%.

Man & Woman of the Year—record-breaking $30.8MM raised; $8MM more than previous year.

LLS announced four Screen to Lead grants to help researchers develop novel small molecules that target genes which cause cancer.
PRESIDENT AND CHAIRMAN’S MESSAGE.

With more than 1.1 million people in the U.S. living with or in remission from a blood cancer, the work of The Leukemia & Lymphoma Society (LLS) has never been more important.

We talk about someday being today. These are not just words. LLS has helped advance innovative therapies, initiated unique research collaborations, provided life-saving programs to help patients and caregivers, and advocated at the state and federal levels to ensure access to quality and affordable care. These efforts have helped bring someday home for many blood cancer patients; they would face even greater treatment and quality of life challenges were it not for the work of LLS.

Fiscal year 2014, our 65th anniversary, proved to be a challenging year of adapting and evolving, but also one of reaching meaningful milestones. This year, LLS surpassed $1 billion of cumulative investments in cancer therapies and saving lives. Innovation requires sustained support from our donors, and their ongoing commitments have been amazing. LLS’s decade-long collaboration with Nike for our Team In Training program helped us surpass the $143 million mark. Our long-time corporate partner, Burlington, raised more than $3 million through their annual campaign.

LLS has been at the heart of many important advances for blood cancer patients during 2014—from new targeted treatments like ibrutinib, to exciting progress in T-cell immunotherapy, to closing the gap between discovery and drug development through four new partnerships in our Therapy Acceleration Program®.

Other successes come from LLS’s advocacy and policy efforts, which are committed to ensuring sustainable access to the best available treatments for all blood cancer patients. Eliminating waiting periods for bone marrow transplants in Oregon and Washington, and establishing parity between insurance coverage for oral and intravenous therapies in Missouri, Maryland, Wisconsin and Arizona, are examples of how LLS’s advocacy initiatives help save lives today.

Also in 2014, our executive leadership changed. In February, LLS CEO John Walter stepped down following nearly 20 years of service. John helped guide the expansion of LLS’s efforts to accelerate new treatments for blood cancers, as well as our Co-Pay Assistance Program, which has provided almost $200 million to help patients afford their insurance premiums and drug co-pays. The Board thanked John for his many years of dedication to our mission. Lou DeGennaro accepted the Board’s request that he follow John as President and CEO, and Lou leveraged his nine previous years with LLS to hit the ground running.

During this past year, we continued building on the success of the powerful LLS brand platform Someday is Today™. This simple message calls to mind our contributions to impactful advances, and differentiates us in an ever more competitive fundraising environment. As you’ll see in the following pages, your contributions to LLS have immediate and lasting power. You give—we act—lives saved. It’s a formula for action that couldn’t be any simpler—or more meaningful.

Louis J. DeGennaro, PhD
President & CEO

Timothy S. Durst, JD
Chairman of the Board
AWARDED SIX $100,000 NEW IDEA AWARDS—a program supporting highly novel research concepts.

LLS HELPED PASS 12 STATE BILLS IN 2014 THAT LIMIT PATIENT COST-SHARING ON SPECIALTY DRUGS, IMPROVE COVERAGE FOR TERMINALLY ILL PATIENTS AND ENSURE TIMELY ACCESS TO TREATMENT.

MANY OF THE NEW GENERATION OF CANCER PATIENTS MANAGE THEIR CONDITION WITH JUST A DAILY PILL.

TEAM IN TRAINING HAS RAISED MORE THAN $1.4 BILLION TO DATE TO HELP FUND OUR MISSION.
FROM HERE TO SOMEDAY: HOW OUR MISSION IS SHORTENING THE DISTANCE.

Partnering for Cures—Therapy Acceleration and the Targets, Leads and Candidates programs.

At the annual Partnering for Cures in New York City, more than 1,000 leaders in medical research came together, driven by a sense of urgency on getting treatments to patients. LLS was there as a leader in venture philanthropy.

Through our Therapy Acceleration Program, we are bridging the gap between discovery and drug development, creating partnerships with universities and biotechnology and pharmaceutical companies to speed the process.

Louis J. DeGennaro, PhD, LLS president & CEO, participated in 30 meetings with other leaders and highlighted our Targets, Leads and Candidates program, through which we partner with the biopharmaceutical industry to fund early-stage research.

T-cell immunotherapy.

LLS-funded research showed remarkable data on chimeric antigen receptor T-cell immunotherapy—CART immunotherapy—at the 55th American Society of Hematology (ASH) Annual Meeting. Among adults and children with advanced blood cancers, 89% of the acute lymphoblastic leukemia (ALL) patients had a complete response rate and 47% of adult chronic lymphocytic leukemia (CLL) patients responded to the therapy, the first successful and sustained use of genetically engineered T cells to fight leukemia.

LLS grant recipient and CART immunotherapy team leader Carl H. June, MD, of the University of Pennsylvania, explained: “Our findings show that the human immune system and these modified ‘hunter’ cells work together to attack tumors in an entirely new way.” Lee Greenberger, PhD, LLS chief scientific officer, added, “These findings show real promise in the quest to activate and direct the immune system to kill cancer cells.”

Over the past 16 years, LLS has committed $21 million to this work through 2017.

Additional funds are being directed to agents that take the brakes off the immune system, the so-called immunocheckpoint inhibitors, vaccines to activate the immune system, as well as new CART therapies where the T cells are directed to other blood cancers, including acute myeloid leukemia (AML).

Ibrutinib study results.

Ibrutinib, a targeted oral therapy approved by the FDA to treat patients with relapsed CLL, made news at the 2014 American Society for Clinical Oncology meeting in Chicago.

John Byrd, MD, of The Ohio State University, and a long-time recipient of LLS funding, presented data from a Phase 3 study that showed ibrutinib significantly outperformed ofatumumab. At six months, 83 percent of patients treated with ibrutinib experienced progression-free survival compared to 49 percent of patients on ofatumumab.
TODAY’S CANCER PATIENTS AREN’T JUST SURVIVING, THEY’RE LIVING.

LLS COMMITTED $7.5MM IN DIRECT RESEARCH FUNDING TO PEDIATRIC CANCER, 9 PERCENT OF OUR TOTAL RESEARCH COMMITMENT.

LLS ADVOCATED FOR THE GABRIELLA MILLER KIDS FIRST RESEARCH ACT, WHICH DEDICATES $120MM OF FEDERAL FUNDING TO PEDIATRIC RESEARCH AND SIGNED INTO LAW BY PRESIDENT OBAMA IN APRIL.

LIGHT THE NIGHT WALK RAISED $58.2MM.
Earlier, Dr. Byrd and colleagues published a study in *The New England Journal of Medicine* identifying mechanisms that cause resistance to ibrutinib, raising hope that understanding these mutations could lead to drug combinations that prevent or treat ibrutinib-resistant CLL.

**Beat AML initiative begins.**

AML is the most common type of acute leukemia among adults, with less than one-third of newly diagnosed patients in the U.S. surviving beyond five years. LLS kicked off its “Harry T. Mangurian, Jr. Beat AML” fundraising initiative in New York City, featuring Brian Druker, MD, Director, Oregon Health & Science University Knight Cancer Institute (OHSU), and lead investigator of LLS’s groundbreaking collaboration with OHSU.

With treatment options for AML largely unchanged in 30 years, Dr. Druker spoke about creating a network of collaborators open to testing new ideas, including drug combinations.

Dr. DeGennaro emphasized bringing together researchers and the U.S. Food and Drug Administration (FDA). “From 2000 through 2013, nearly 40 percent of the new anti-cancer treatments approved by the FDA were first approved for blood cancer patients. That’s more first approvals than for any other group of cancer patients,” he noted.

**ASH Annual Meeting.**

At the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, researchers from around the world shared the latest findings on targeted therapies, immunotherapies and epigenetics. Topics included the recently approved obinutuzumab, an antibody that helps kill blood cancer cells that express a protein found in many B cell lymphomas.

“LLS funds research from early clinical work to clinical trials, and even partners with industry, to accelerate therapies through the drug discovery pipeline,” said Dr. Greenberger. “Our investments have helped advance therapies that are saving lives today.”

Also, LLS hosted a satellite symposium on how cancer genomics and technology combine to advance new therapies for treatment of blood cancer patients.

**Translational Research Program (TRP) 20th anniversary.**

Our Translational Research Program, designed to advance promising discoveries from lab to clinic, celebrates 20 years of helping to advance the work of some of the most renowned blood cancer researchers, including Brian Druker, MD, of Oregon Health & Science University, Carl June, MD, of the University of Pennsylvania, and John Byrd, MD, of the Ohio State University.

LLS is proud of supporting the work of Dr. Druker. His breakthrough studies of the targeted oral therapy, imatinib (Gleevec®), and later clinical trials led to the accelerated FDA approval of the drug that is now saving lives of patients with chronic myeloid leukemia (CML), and helping patients with other cancers as well. A video about Dr. Druker can be viewed on our YouTube Channel.
LLS HELPED ACHIEVE ORAL PARITY LEGISLATION IN 6 STATES; CURRENT TOTAL IS 33 STATES PLUS D.C.

IN 65 YEARS OF INVESTING IN CANCER THERAPIES AND SAVING LIVES, LLS SURPASSED THE $1B MILESTONE.

FOR LLS, THE UFCW RAISED $2.6MM IN CANADA AND $1.9MM IN THE U.S.

LLS SUPPORTED $15MM IN SPECIALIZED CENTER OF RESEARCH GRANTS.
State policy: Eliminating waiting periods for transplants in Oregon and Washington.

LLS mobilized advocacy efforts to successfully reverse a 24-month waiting period for previously uninsured bone marrow transplant patients in the Oregon health insurance marketplace. LLS’s access team brought this issue to the attention of the public and state health policy officials to help remove this barrier to a critical therapy for the patients who urgently need it.

Similar action also reversed a 3-month waiting period in Washington state. These are important examples of how LLS’s advocacy initiatives work to save lives every day.

New Oral parity laws became reality in 4 states.

LLS advocacy helped make oral parity a reality in Missouri, Maryland, Wisconsin and Arizona. Oral parity requires insurance plans to charge consistent co-payments, deductibles, or coinsurance amounts for anticancer medications, regardless of whether the therapy is self-administered or administered intravenously or by injection.

Equitable access to oral therapies allows blood cancer patients and their doctors to decide the most clinically appropriate treatment and keeps patients from having to choose whether or not they can afford to fill their prescription.

The LLS government affairs team, along with our advocates, directly contributed to the passage of oral parity bills in five states in the last two years and a total of ten oral parity bills.

LLS patient support for the Affordable Care Act (ACA).

LLS played an active role in informing the public about the effect the ACA could have on blood cancer patients and the types of questions to ask their insurance companies. ACA bans lifetime limits on care, and allows dependents to stay on their parent’s health insurance up to age 26. Consumers with pre-existing conditions such as a blood cancer cannot be denied coverage based on their health status.

While there are many beneficial aspects of the law, there are also issues that blood cancer patients need to be aware of, such as narrow networks and high cost-sharing, which can prevent patients from getting access to the care they need.

LLS’s Information Resource Center (IRC), as well as local patient support staff, helped patients understand their options and eligibility for insurance subsidies when signing up for coverage through the new federal and state marketplaces.

The Affordable Care Act: Milliman report raises concerns for blood cancer patients.

LLS continues to be a resource for our patients. As part of LLS’s efforts to help educate patients about the Affordable Care Act, we commissioned the Milliman Report on Healthcare Exchanges in Seven States. It provided a look at the 2014 individual benefit designs, coverage benefits and premiums for policies sold on seven state health insurance exchanges—California, New York, Florida, Texas, New Jersey, Michigan and Washington. Narrow networks and high cost-sharing were among the concerns raised.
LLS EXPANDED IRC HOURS TO 9 A.M. – 9 P.M. EASTERN TIME.

IRC SPECIALISTS PERFORMED 6,000 CLINICAL TRIAL SEARCHES USING LLS’S TRIALCHECK TOOL.

INFORMATION RESOURCE CENTER (IRC) SPECIALISTS FIELDED 62,000+ INQUIRIES; TOUCHING MORE THAN 1MM PATIENTS SINCE ITS INCEPTION IN 1987.

LLS PARTICIPANTS IN THE NIKE WOMEN’S MARATHON SAN FRANCISCO RAISED $9MM; NIKE WOMEN’S HALF MARATHON IN D.C., $4.7MM.

LLS-FUNDED RESEARCHERS REPORTED THAT 27 OF 30 ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS TREATED WITH CTL-019 EXPERIENCED COMPLETE REMISSION.
Federal policy: Kids First Research Act.

The Gabriella Miller Kids First Research Act increases much needed funding for pediatric medical research activities administered through the Common Fund of the National Institutes of Health.

This law expands pediatric research activities into cancer, autism and other diseases impacting children.

The law was passed by both the House of Representatives and the Senate, then signed into law by President Obama. LLS played a key role in advocating on behalf of this important piece of legislation.

LLS Co-Pay Assistance Program milestone.

LLS has raised more than $200 million for our Co-Pay Assistance Program since its inception in 2007. The program provides support for prescription drug co-pays and health insurance premiums for blood cancer patients who meet certain income requirements. Patients with private insurance, Medicare beneficiaries under Medicare Part B and/or Plan D, Medicare Supplementary Health Insurance and Medicare Advantage are eligible.

Through our Co-Pay Assistance Program, LLS has made blood cancer treatments available and affordable for more than 36,000 patients to date.

IRC expands patient service.

LLS has expanded hours for its Information Resource Center (IRC), a toll-free call center staffed with master’s level healthcare professionals knowledgeable on the latest information on all blood cancers.

The call center can immediately assist callers in English, Spanish and French, with translations available in more than 140 languages.

LLS’s IRC stands out among health organization call centers because of the depth of individualized attention offered. Since its inception in 1987, the IRC has helped more than one million callers.

Increasing service hours is part of our strategic plan to expand mission offerings. We provide support services to patients and families, ensuring patients have access to quality, affordable care.
SINCE THE EARLY 1960S, FIVE-YEAR SURVIVAL RATES FOR MANY BLOOD CANCER PATIENTS HAVE DOUBLED, TRIPLED OR EVEN QUADRUPLED.

LLS FORMED COLLABORATIONS WITH FOUR NEW TAP PARTNERS—INCLUDING ARGENX, STEMLINE, AFFIMED AND STANFORD UNIVERSITY—25 ACTIVE PROGRAMS IN TOTAL.

LLS COMMITTED $23MM IN TRANSLATIONAL RESEARCH PROGRAM GRANTS, ADDRESSING AREAS OF UNMET MEDICAL NEED, AND HELPING ADVANCE PROJECTS FROM LAB TO CLINIC.

SCHOOL & YOUTH RAISED $27.3MM.
HOW WE’RE GETTING EVERYONE INVOLVED IN OUR MISSION.

Donor Development—Mission Critical.

Donor Development also experienced a record-setting year for LLS, raising $29.2 million. The year was highlighted by the launching of the $8.3 million Beat AML fundraising campaign. To date, $6.5 million has been pledged, spearheaded by the Harry T. Mangurian, Jr. Foundation’s lead gift of $4 million. Long-time LLS volunteer Michael Copley is serving as the National Chair of the three-year campaign motivated by the loss of his young daughter who passed from AML two decades ago.

Major Gifts, donations of $10,000 or more, directly funded countless other mission critical programs ranging from new research in our scientific pediatric portfolio to greater outreach through our Transportation Assistance Fund. An additional $5.3 million was realized via bequests, a true lasting legacy to LLS’s mission and our quest for cures and access for all touched by blood cancers.

Scientific American Worldview editorial.

A Scientific American Worldview editorial written by Dr. DeGennaro focuses on how nonprofits can be catalysts for collaboration to advance new therapies and cures.

By enabling drug discovery from beginning to end—identifying urgent unmet medical needs, creating partnerships with biopharmaceutical companies and academic research, and with a milestone-driven agenda to manage product development projects—DeGennaro illustrates how the process can be accelerated.

The article addresses specific challenges faced in treating acute myeloid leukemia and details how LLS joined with Brian Druker, MD, Oregon Health & Science University, to make precision medicine a reality.
The survival rate for myeloma more than tripled since the 1960s.

The first oral therapy targeting B-cell cancers was FDA-approved for patients with relapsed CLL and mantle cell lymphoma.

In June, the Leukemia Cup regatta passed $50MM support since the first event in 1987.

On mission day in May, 375 advocates attended 329 meetings on Capitol Hill. We collected 16,589 signatures demanding elected officials expand access to treatment for cancer patients and their families.
BREAKTHROUGH FUNDRAISING AND 
THE SUCCESS OF OUR MISSION.

LLS: Leading the way to a world without blood cancers.

For 65 years, LLS has been helping to lead the way to a world without blood cancers. This year, LLS surpassed a momentous milestone: We have invested more than $1 billion in research to promote our cause, find cures and achieve a world without blood cancers.

At a three-day conference in Washington, D.C., all aspects of our cures and access agenda were discussed. Our advocacy enables us to impact the public policy discussion on federal legislative and regulatory issues that affect patient access.

On the steps of Capitol Hill, as one of 375 advocates, Ethan Zohn, star of “Survivor: Africa,” and a two-time Hodgkin lymphoma survivor, implored, “What’s the point of research if patients don’t have access to the therapies?”

Charles Esten, an actor/musician who plays Deacon Claybourne on the TV show “Nashville”, performed for the excited crowd. Esten has supported LLS since his young daughter, now a survivor, was diagnosed with leukemia.

Jessica Melore, a motivational speaker and dedicated LLS volunteer, suffered a heart attack at age 16, endured a heart transplant, a leg amputation and is a two-time lymphoma survivor now six years in remission. She spoke of the urgency of the LLS mission: “LLS isn’t satisfied with finding a cure 50 years from now. Someday is today.”

A giant “Declare It!” wall engaged attendees in our movement, declaring “Cancer Ends with Me.”

Burlington Stores and Light The Night.

For the 12th consecutive year, Burlington Stores, with its more than 520 locations nationwide, joined the LLS Light The Night® Walk campaign to raise funds to help find cures and ensure access to treatments for patients with blood cancer. The national off-price retailer encouraged its customers to make a donation at check-out and enrolled 28,000 associates to participate in Light The Night Walks all across the country.

Over a 17-week campaign, Burlington, LLS’s number one national corporate partner, raised more than $3 million, bringing the total raised over the many years of partnership to more than $19 million. “By engaging our generous customers and associates, our partnership with LLS and The Light The Night Walk enables us to help fund life-saving cancer research and treatments in a meaningful way,” said Tom Kingsbury, President and CEO of Burlington Stores.
LLS advocated to eliminate Oregon’s 2-year waiting period for stem cell transplants for previously uninsured blood cancer patients.

The Patti Robinson First Connection Program, a free LLS service, matched 4,518 patients and loved ones with a trained volunteer who has shared a similar experience.

Moms in Training, a new extension of Team in Training, enlisted 1,000 moms in 36 chapters to raise almost $1MM.

LLS provided $49.2MM in co-pay support to blood cancer patients.
Nike and 10 years of saving lives.

The Nike Women’s Marathon San Francisco celebrates women coming together through the shared passion of taking on a physical endurance challenge while also taking aim at cancer.

October 2013 marked the 10th annual Nike Women’s Marathon San Francisco. Among 30,000 participants from around the world were 2,900 members of LLS’s Team In Training, who raised more than $9 million to help LLS find cures for blood cancers and ensure access to treatments for patients.

UFCW supports LLS.

The United Food and Commercial Workers (UFCW), the union representing grocery and other retail workers, has been a dedicated LLS partner since 1983. The union has raised more than $60 million to help LLS advance its mission over that time. Its 1.3 million union members are truly helping blood cancer patients live better, longer lives.

In fiscal year 2014 alone, the union generated more than $2.6 million in Canada and $1.9 million for LLS in the U.S. Significant in its fundraising effort in Canada is the annual “Returns For Leukemia” bottle drive, organized by UFCW Local 12R24 and The Beer Store. This Ontario campaign converts deposits on bottles into donations. Canadian members also participate in other fundraising events, including golf tournaments, dinners and auctions, and participation in LLS campaigns.

Man & Woman of the Year record-breaking year.

For their support of LLS’s mission, two leading fundraisers were named the 2014 National Man & Woman of the Year, the 24th annual awards for this prestigious program. The record-breaking campaign total of $30.8 million is nearly $8 million more than was raised last year.

Dr. Christos Giannoulias of Chicago and Samara Wolpe of Los Angeles earned this coveted title. These two “Champions of Hope” were among 900 candidates from across the country to vie for the award.

The new All Star Alumni campaign was launched to give Man & Woman of the Year alumni the opportunity to use their talents, contacts and creativity to represent their local campaign on a larger platform. Six returning competitors raised $484,940 to support LLS’s work. The two national All Star winners were Kim Tindall and Ryan LaFontaine. The new initiative also highlighted the fact that LLS’s job is not done until all blood cancer patients have cures and access to the treatments they need.
The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hasten the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is composed of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD 2013
Walter & Eliza Hall Institute of Medical Research

Frederick Alt, PhD 2012
Boston Children’s Hospital

Jon Aster, MD 2013
Brigham & Women’s Hospital

Dr. John Byrd is funded in part by
Rita Cavanagh & Gerald Kafka,
University of Pennsylvania

John Byrd, MD 2011
Baylor College of Medicine

Helen Heslop, MD 2014
University of California, San Francisco

The Jim Jacobs Charitable Foundation

The Board of Trustees of the Leland Stanford Junior University

Mary Eapen, MD 2010
Medical College of Wisconsin

Benjamin Ebert, MD, PhD 2013
Brigham & Women’s Hospital

Anthony Green, MD, PhD 2012
University of Pennsylvania

John Byrd, MD 2011
Brigham & Women’s Hospital

Dr. Irene Ghobrial is funded in part by
Orokawa Foundation.

Imagine a Cure for Leukemia and The Cora and John H. Davis Foundation,
Dana-Farber Cancer Institute

Jennifer Brown, MD, PhD 2011
Mount Sinai School of Medicine

Craig Bassing, PhD 2011
The Children’s Hospital of Philadelphia

Dr. Scott Armstrong is fully funded by
Baker Botts L.L.P.

Scott Armstrong, MD, PhD 2010
Mount Sinai School of Medicine

Matthew Carroll, MD 2014
University of Illinois - Chicago

Dr. Patrick Brown is fully funded by

Baker Botts L.L.P.

Iain Cheeseman, PhD 2013
Whitehead Institute for Biomedical Research

Jing Chen, PhD 2011
Emory University

Yuh Min Chook, PhD 2011
The University of Texas Southwestern Medical Center

Dipanjan Chowdhury, PhD 2015
Dana-Farber Cancer Institute

Christopher Cogle, MD 2013
University of Florida

Yali Dou, PhD 2013
University of Michigan

Mary Eapen, MD 2010
Medical College of Wisconsin

Benjamin Ebert, MD, PhD 2013
Brigham & Women’s Hospital

Thomas Fazzio, PhD 2015
University of Massachusetts Medical School

Elisa Flores, PhD 2012
The University of Texas MD Anderson Cancer Center

Maxim Frolov, PhD 2011
University of Illinois - Chicago

Andrei Goga, MD, PhD 2013
University of Medicine and Dentistry of New Jersey, New Brunswick

Mary Eapen, MD 2010
Medical College of Wisconsin

William Matsui, MD 2010
Johns Hopkins University School of Medicine

Hanna Mikkola, MD, PhD 2012
University of California, Los Angeles

Golam Mohi, PhD 2014
SUNY Upstate Medical Center

James Mulloy, MD 2013
Children’s Hospital Medical Center-Cincinnati

Markus Muschen, MD 2011
University of California, San Francisco

Emmanuelle Passegué, PhD 2015
University of South Carolina

Raoul Tibes, MD, PhD 2015
Mayo Clinic Arizona

Wei Tong, PhD 2014
The Children’s Hospital of Philadelphia

David Traver, PhD 2013
University of California, San Diego

Matthew Walter, MD 2014
Washington University of St. Louis School of Medicine

Hengbin Wang, PhD 2013
The University of Alabama at Birmingham

Wenyi Wei, PhD 2014
Beth Israel Deaconess Medical Center

David Weinstock, MD 2014
Dana-Farber Cancer Institute

Noopur Raje, MD 2010
Massachusetts General Hospital

Shan Zha, MD, PhD 2014
University of Virginia

Johnathan Whetstine, PhD 2015
University of Pennsylvania

Corey Stemp, MD 2013
University of Pennsylvania

Dr. Patrick Brown is fully funded by

Baker Botts L.L.P.

Iain Cheeseman, PhD 2013
Whitehead Institute for Biomedical Research

Jing Chen, PhD 2011
Emory University

Yuh Min Chook, PhD 2011
The University of Texas Southwestern Medical Center

Dipanjan Chowdhury, PhD 2015
Dana-Farber Cancer Institute

Christopher Cogle, MD 2013
University of Florida

Yali Dou, PhD 2013
University of Michigan

Mary Eapen, MD 2010
Medical College of Wisconsin

Benjamin Ebert, MD, PhD 2013
Brigham & Women’s Hospital

Thomas Fazzio, PhD 2015
University of Massachusetts Medical School

Elisa Flores, PhD 2012
The University of Texas MD Anderson Cancer Center

Maxim Frolov, PhD 2011
University of Illinois - Chicago

Andrei Goga, MD, PhD 2013
University of Medicine and Dentistry of New Jersey, New Brunswick

Mary Eapen, MD 2010
Medical College of Wisconsin

William Matsui, MD 2010
Johns Hopkins University School of Medicine

Hanna Mikkola, MD, PhD 2012
University of California, Los Angeles

Golam Mohi, PhD 2014
SUNY Upstate Medical Center

James Mulloy, MD 2013
Children’s Hospital Medical Center-Cincinnati

Markus Muschen, MD 2011
University of California, San Francisco

Emmanuelle Passegué, PhD 2015
University of South Carolina

Raoul Tibes, MD, PhD 2015
Mayo Clinic Arizona

Wei Tong, PhD 2014
The Children’s Hospital of Philadelphia

David Traver, PhD 2013
University of California, San Diego

Matthew Walter, MD 2014
Washington University of St. Louis School of Medicine

Hengbin Wang, PhD 2013
The University of Alabama at Birmingham

Wenyi Wei, PhD 2014
Beth Israel Deaconess Medical Center

David Weinstock, MD 2014
Dana-Farber Cancer Institute

Noopur Raje, MD 2010
Massachusetts General Hospital

Shan Zha, MD, PhD 2014
University of Virginia

Johnathan Whetstine, PhD 2015
University of Pennsylvania

Corey Stemp, MD 2013
University of Pennsylvania

Dr. Patrick Brown is fully funded by

Baker Botts L.L.P.
The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Alison Adams, PhD 2014
Yale University
Cassandra Adams, PhD 2013
University of California, San Francisco
Koshi Akahane, MD, PhD 2014
Dana-Farber Cancer Institute
Spencer Alford, PhD 2015*
The Board of Trustees of the Leland Stanford Junior University
Lucas Baitsch, PhD 2013
Dana-Farber Cancer Institute
Burton Barnett, PhD 2015*
The Regents of the University of California, San Diego
Cora Bergantinos, PhD 2015*
University of California, San Francisco

* Newly awarded or renewed grants in fiscal year 2015
RESEARCH GRANTS (continued)

Shih-Chieh Ti, PhD 2014
The Rockefeller University
Anastasia Tikhonova, PhD 2015*
New York University
School of Medicine
Joanna Tober, PhD 201216
University of Pennsylvania
Gianluca Varetti, PhD 2014
Dana-Farber Cancer Institute
Isana Vekler-Lubliniski, PhD 2015*
University of Massachusetts
Medical School
Youzhong Wan, PhD 2013
Dana-Farber Cancer Institute
Lin Wang, PhD 2013
University of California, Berkeley
Matthew Warr, PhD 2013
University of California, San Francisco
Nathan Westcott, PhD 2014
The Rockefeller University
Jennifer Woyach, MD 2013
The Ohio State University
Mingyi Xie, PhD 2013
Yale University
Xiaodi Yu, PhD 2014
Children’s Hospital Boston
Chongzhi Zang, PhD 2013
Dana-Farber Cancer Institute
Joshua Zeldner, MD 2015*
University of North Carolina at Chapel Hill
Haojian Zhang, PhD 2014
Dana-Farber Cancer Institute
Yu Zhang, PhD 2015*
Children’s Hospital Boston
Grace Zheng, PhD 2013
The Board of Trustees of the Leland Stanford Junior University
Bo Zhou, PhD 2013
The University of Texas
Southwestern Medical Center

Jennifer Brown, MD, PhD 2013
Dana-Farber Cancer Institute
Jose Cancelas, MD, PhD 2013
Cincinnati Children’s Hospital
Medical Center
Jennifer Carew, PhD 2013
The University of Texas Health Science Center at San Antonio
Lucio Castilla, PhD 2015*
University of Massachusetts Medical School
Leandro Cerchietti, MD 2014
Well Medical College of Cornell University
Xiubo Chang, PhD 2014
Mayo Clinic Arizona
Jianjun Chen, PhD 2014
The University of Chicago
Selina Chen-Kiang, PhD 2011
Well Medical College of Cornell University
Eric Chow, MD 2013
Fred Hutchinson Cancer Research Center
Tomasz Cierpicki, PhD 2014
University of Michigan
Curt Civan, MD 2014
University of Maryland
James Coghill, MD 2015*
University of North Carolina at Chapel Hill
Leif Bergsagel, MD 2013
Mayo Clinic Arizona
Irwin Bernstein, MD 2013
Fred Hutchinson Cancer Research Center
Ravi Bhatia, MD 2014
Beckman Research Institute of the City of Hope
Smita Bhatia, MD, MPH 2013
Beckman Research Institute of the City of Hope
Bruce Blazar, MD 2015*
University of Minnesota
Katherine Borden, PhD 2014
University of Montreal

Elizabeth Eklund, MD 2014
Northwestern University
Rudi Fasan, PhD 2014
University of Rochester
Adolfo Ferrando, MD, PhD 2015*
Columbia University Medical Center
Maria Figueroa, MD 2014
Well Medical College of Cornell University
Stephen Forman, MD 2014
Beckman Research Institute of the City of Hope
Mark Frattini, MD, PhD 2015*
Columbia University Medical Center
Paul Frenette, MD 2015*
Albert Einstein College of Medicine of Yeshiva University
Karim Gaensler, MD 2014
University of California, San Francisco
Patricia Gallagher, PhD 2014
Wake Forest University Health Sciences
Irene Ghozrial, MD 2013
Dana-Farber Cancer Institute
Steven Grant, MD 2015*
Virginia Commonwealth University
Timothy Graubert, MD 2013
Washington University in St. Louis
James Griffin, MD 2013
Dana-Farber Cancer Institute
H. Leighton Grimes, MD 2013
Cincinnati Children’s Hospital Medical Center
Monica Guzman, PhD 2013
Well Medical College of Cornell University
Duane Hassan, PhD 2013
Well Medical College of Cornell University
Christoph Heuck, MD 2013
University of Arkansas for Medical Sciences
Ronald Hoffman, MD 2013
Mount Sinai School of Medicine
Robert Hromas, MD 2013
University of Florida
Javeed Iqbal, PhD 2014
University of Nebraska Medical Center
Richard Jones, MD 2015*
Johns Hopkins University School of Medicine
Andrew Kung, MD, PhD 2015*
Columbia University Medical Center
John Kuruvilla, MD 2013
University Health Network
Dean Lee, MD, PhD 2014
The University of Texas
MD Anderson Cancer Center
Anthony Letai, MD, PhD 2013
Dana-Farber Cancer Institute
Ross Levine, MD 2013
Memorial Sloan Kettering Cancer Center
Mignon Loh, MD 2015*
University of California, San Francisco
A. Look, MD 2013
Dana-Farber Cancer Institute
Thomas Loughran, MD 201420
University of Virginia
Leo Luznik, MD 2013
Johns Hopkins University School of Medicine
Jaroslav Maciejewski, MD, PhD 2013
Cleveland Clinic Foundation
Ivan Maillard, MD 2015*
University of Michigan
Markus Muschen, MD, PhD 2014
University of California, San Francisco
Nicolas Natter, MD, PhD 2014
Columbia University Medical Center
Ruben Niesvizky, MD 2013
Weill Medical College of Cornell University
Owen O’Connor, MD, PhD 2013
Columbia University Medical Center
Tiong Ong, MD 2013
National University of Singapore
Christopher Park, MD, PhD 2014
Memorial Sloan Kettering Cancer Center
Alessandra Pernis, MD 2014
Hospital for Special Surgery
Javier Pinilla, MD, PhD 2015*
Lee Moffitt Cancer Center & Research Institute
Karen Rabin, MD 2014
Baylor College of Medicine
Anjana Rao, PhD 2015*
La Jolla Institute for Allergy and Immunology
Pavan Reddy, MD 2013
University of Michigan
Katy Rezvani, MD, PhD 2015*
The University of Texas
MD Anderson Cancer Center

16 Dr. Joanna Tober is The HM Insurance Group Special Fellow.
17 Dr. Stephen Ansell is funded in part by The Adam–Robertson Family.
18 Dr. Soro Armenain is funded in part by the California Community Foundation.
19 Dr. H. Leighton Grimes is funded in part by The Marge & Charles J. Schott Foundation.
20 Dr. Thomas Loughran is funded in part by the Jane Elissa/Charlotte Meyers Endowment Fund.
21 Dr. Matthew Matasar is funded in part by the Jane Elissa/Charlotte Meyers Endowment Fund.
22 Jeffrey Molldrem is the Imagine a Cure for Leukemia’s Translational Researcher.
James Rubenstein, MD, PhD 2014
University of California, San Francisco
Daniela Salvemini, PhD 2013
Saint Louis University
Aaron Schimmer, MD, PhD 2015
University Health Network
Neil Shah, MD, PhD 2013
University of California, San Francisco
Matthew Shair, PhD 2014
President & Fellows of Harvard College
Margaret Shipp, MD 2013
Dana-Farber Cancer Institute
Ulrich Steidl, MD, PhD 2014
Albert Einstein College of Medicine of Yeshiva University
Y. Lynn Wang, MD, PhD 2013
University of Michigan
Ryan Wilcox, MD, PhD 2013
University of Texas, Dallas
David Wiest, PhD 2014
The University of Chicago
The J. David Gladstone Institutes
Kenneth Anderson, MD 2015
Northwestern University
John Byrd, MD 2015
University of Virginia
A. Keith Stewart, MD 2013
Albert Einstein College of Medicine of Yeshiva University
A. Keith Stewart, MD 2013
New York, NY

PARTNERSHIPS

Acetylon Pharmaceuticals, Inc.
Baltimore, MD
Affimed Therapeutics AG
Heidelberg, Germany
arGEN-X BV
Breda, Netherlands
BioTherix, Inc.
Chappaqua, NY

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Hoibrook Kohrt, MD, PhD
The Board of Trustees of the Leland Stanford Junior University The Learning Collaborative Kansas City, KS

Ari Melnick, MD
Weill Medical College of Cornell University

Daniel Pollyea, MD
University of Colorado

Yogen Saunthararajah, MD
Cleveland Clinic

Aaron Schimmer, MD, PhD
University Health Network

Shape Pharmaceuticals, Inc.
Cambridge, MA

Stemline Therapeutics, Inc.
New York, NY

Valor Biotherapeutics, LLC
Dallas, TX


**Newly awarded or renewed grants in fiscal year 2015**

† Partner grants with the International Waldenstrom’s Macroglobulinemia Foundation (WMF).
RESEARCH PORTFOLIOS

LLS Research Portfolios are groups of research projects organized around a specific focus within our research portfolio during this fiscal year.

Acute Lymphoblastic Leukemia

1. Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Megan’s Wings Foundation.

2. Acute Myeloid Leukemia and Myelodysplastic Syndromes

3. Chronic Lymphocytic Leukemia

4. Chronic Myeloid Leukemia

5. Hodgkin Lymphoma

6. Immunotherapy

7. Mantle Cell Lymphoma

8. Myeloma and Waldenstrom Macroglobulinemia

9. Aggressive Non-Hodgkin Lymphoma

10. Indolent Non-Hodgkin Lymphoma

11. Pediatric and Young Adult Blood Cancer

12. Quality of Life

13. Stem Cell Transplantation Research Portfolio

14. Therapy Acceleration Program

15. The Harry T. Mangurian, Jr. Beat AML Project

ENDOWMENT FUNDS

The Bill Beattie Memorial Endowment Fund (Alabama)

The Virginia Major Brooks Memorial Endowment Fund

The Rachel Kudish Fund

The Rae Endowment Fund (Ontario)

The Harry T. Mangurian, Jr. Beat AML Project

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by The Hildegarde D. Becher Foundation, Inc., the David Giguilfoile Legacy Foundation, Mike Goliner, Pat and Lou Manzi, William McInitt, Melody’s Fund, and Pat and Jeff Sachs.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Madeline and Stephen Anbinder, the George L. Shields Foundation, Inc., Sandi and Stan Kahan, Thomas Keley, and Robin D. and Jonathan Klein.

Chronic Myeloid Leukemia Research Portfolio is funded in part by Leslie & Dr. Larry Nance and Charles Foundation and Becky Goldchaux.

Hodgkin Lymphoma Research Portfolio is funded in part by Baltimore Tour de Court XII in memory of Rachel Minkove, and Pravair, Inc., Janet & Alex Boggs and Jami and Edward Levy.

Immunotherapy Research Portfolio is funded in part by Andrew F. Gulli.

Mantle Cell Lymphoma Research Portfolio is funded in part by Andrew F. Gulli.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by the Names Family Foundation.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Lisa and Craig Hawkins and the Slice of Lime Foundation.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by Nonnie and John Barbee, Susan and Jay Clark, Tom Harrison, Chris Kolb, Cristine and Timothy Lindenfelscher, Cambria and Brian Reinsborough, Lois and Jerry Rosenblum, Beth Saltor and Gloria, and Miss Leslie Weiss.

Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by the A.C.E. Family Foundation, the Mangurian M. Cornell Foundation, Jennifer and David Comar, Franklin American Mortgage Company, The Hershey Company, Hockey Fights Cancer, Parents Against Leukemia, Cynthia & Steven Rigby, Take a Swim Against Cancer - Bucks County Aquatic Swim Teams, Team Ryan, The Thomas and Agnes Carvel Foundation, the Virginia Tech FarmHouse Fraternity, and Yvonne and Tauer Youssett.

Quality of Life Research Portfolio is funded in part by The Cherry Picker Foundation, The Escher Foundation - Doris J.W. Escher, MD, the Hamill Family Trust, and The Hildegarde D. Becher Foundation, Inc.

Stem Cell Transplantation Research Portfolio is funded in part by the Rogers Family Foundation.


EDUCATION PROGRAMS


ADVISORS

Franklin O. Smith, MD
University of Cincinnati
A. Keith Stewart
Mayo Clinic and Foundation
Cheryl Willman, MD
University of New Mexico

Medical + Scientific Affairs Committee

Steven Rosen, MD
City of Hope
Chair

Steven Bernstein, MD
University of Rochester Medical Center

Alexandra Mayes Birnbaum
Peartree Publishing

James Bradner, MD
Dana-Farber Cancer Institute

Alan D’Andrea
Dana-Farber Cancer Institute

James H. Davis, PhD, JD
Sandra Horning, MD
Genentech, Inc.

Catriona Jamieson, MD, PhD
University of California, San Diego

Ross Levine
Memorial Sloan Kettering Cancer Center

Jonathan Licht, MD
Northwestern University

Alan List, MD
H. Lee Moffitt Cancer Center

Susan M. O’Brien, MD
The University of Texas MD Anderson Cancer Center

Owen Connor, MD, PhD
Columbia University Medical Center

ENDOWMENT FUNDS

Mary & Robert Bronstein Memorial Fund

The Virginia Major Brooks Memorial Endowment Fund

de Villiers Endowment Fund

Thomas M. Ford Memorial Fund

GlaxoSmithKline Foundation–Gertrude B. Elion Endowment Fund

GlaxoSmithKline, Inc. Research Fund

Jim Jacobs Leukemia Research Fund

Jane Elissa/Charlotte Meyers Endowment Fund

Vushali Ranadive Fellowship Fund

Reich Endowment Fund

The UFCW (Canada) Endowment Fund

Dana Callow, MBA
Boston Millennia Partners

Chair

James Bradner, MD
Dana-Farber Cancer Institute

Joseph Catino, PhD
Retired from Bayer

C. Casey Cunningham, MD
Santé Ventures

James H. Davis, PhD, JD
Retired from Human Genome Sciences, Inc.

Ian W. Flinn, MD, PhD
Tennessee Oncology

Jennifer Gordon, PhD, JD
Paul, Weiss, Rifkind, Wharton & Garrison LLP

Ross Levine, MD
Memorial Sloan Kettering Cancer Center

Susan M. O’Brien, MD
The University of Texas MD Anderson Cancer Center

J. Fred Pritchard, PhD
Celeron
The below listing is made up of individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

**LEADERSHIP CIRCLE $1,000,000 AND ABOVE**

Barclays  
The Beer Store  
Burlington  
Celgene Corporation  
Edward P. Evans Foundation  
Genentech, Inc.  
The Harry T. Mangurian, Jr. Foundation, Inc.  
The Paul E. Singer Family Foundation  
Pharmaceutical Companies  
Pharmacyclics/Janssen Foundation  
The Paul E. Singer Family Foundation  
Restaurant  
Teva Pharmaceuticals

**VISIONARY $250,000 – $499,999**

Austaco, Ltd.  
Carter's, Inc.  
Elbit Systems of America  
F.M. Kirby Foundation, Inc.  
Foundation Beyond Belief  
Global Franchise Group  
Great American Cookies  
Lang/Stiltz Family Fund  
Cristine & Timothy Lindenfelser*  
MaggieMoo’s Ice Cream & Treatery  
Marble Slab Creamery  
The Orokawa Foundation  
Pfizer, Inc.  
Pretzelmaker  
Salesforce.com  
Spectrum Pharmaceuticals, Inc.  
Stater Bros. Charities  
Thomas J. and Gerd Perkins Foundation  
Kathryn & Leo Vecellio*  
Wells Fargo  
Janice & Peter Brock*  
BTIG, LLC  
CA Technologies  
California Community Foundation*  
Cancer Treatment Centers of America  
CareFirst BlueCross BlueShield  
CHMB  
The Coleman Foundation*  
Community Health Charities of New England  
Crue planner - American Express Travel  
Deloitte  
Ernst & Young LLP  
EZCorp  
FIS Foundation  
Fleming’s Prime Steakhouse & Wine Bar  
GEICO  
Patricia & Christsos Giannoulias  
Gilead Sciences, Inc.  
Global Traveler  
Google  
The Harry & Jeanette Weinberg Foundation, Inc.  
Imagine a Cure for Leukemia  
Jason’s Deli  
KPMG LLP  
W. Robert Lappin Trust  
LLS New York City Chapter Board of Trustees  
The Marge & Charles J. Schott Foundation*  
Clyde S. McGregor & LeAnn Pedersen-Pope in memory of Joan Kowing McGregor  
Mercedes Benz  
Merchandise Pickup Service, Inc.  
Missouri Foundation for Health*  
Onyx Pharmaceuticals, Inc.  
The Pamela B. Katten Memorial Leukemia Research Foundation  
PhRMA  
Donald I. Porteous  
PwC  
Nancy C. & Richard Rogers  
Sarah Cannon  
Blood Cancer Network  
Stephen Scherr  
Silicon Valley Bank  
Spice TV  
Daneen & Charles Stiefel  
TIAA-CREF  
Toyota  
Vistar  
VITAS Innovative Hospice Care  
Walgreens  
Gloria, Ellie & Mark Weissberg  
Anonymous (1)

**INNOVATOR $30,000 – $99,999**

ABM Janitorial Services - Midwest LLC  
A.C.E. Family Foundation  
Accenture  
Adami-Roberson Family*  
Alon 7-Eleven  
Alto-Shaam, Inc.  
American Airlines  
Jean & C.E. Andrews*  
Anthony and Jeanne Pritzker Family Foundation  
Bank of America  
Janet & Alex Boggs*  
Booz Allen Hamilton  
Briggs Equipment Services  
Mr. & Mrs. Morris Brown  
C.H. Robinson Worldwide, Inc.  
Emily & Neil Kishter  
The Kroger Co.  
Labors’ Charitable Foundation  
Lehigh Valley Restaurant Group  
Paul Leinwand  
Steven Lieblich  
Lighthouse Investment Partners, LLC  
Michael Maggi  
Gina Manos  
Marsh supermarkets, Inc.  
Melody’s Fund  
Molson Coors  
Mary Miner  
Gary Moy  
Native American Cash Systems  
Anonymous (2)

**PATRON $100,000 – $249,999**

ADP  
Alex and Ani  
The Amgen Foundation  
Astellas USA Foundation  
Baker Botts L.L.P.  
Baptist Health South Florida  
Dr. Evelyn Bata  
Douglas H. Baughman  
BDO  
Biogen Idec  
The Blackstone Charitable Foundation  
BMC  
Bristol-Myers Squibb Company  
Candace and Andrew F.Gulli  
CareFirst BlueCross BlueShield  
CHMB  
The Coleman Foundation*  
Astrazeneca  
Community Health Charities of New England  
Crue planner - American Express Travel  
Deloitte  
Ernst & Young LLP  
EZCorp  
FIS Foundation  
Fleming’s Prime Steakhouse & Wine Bar  
GEICO  
Patricia & Christsos Giannoulias  
Gilead Sciences, Inc.  
Global Traveler  
Google  
The Harry & Jeanette Weinberg Foundation, Inc.  
Imagine a Cure for Leukemia  
Jason’s Deli  
KPMG LLP  
W. Robert Lappin Trust  
LLS New York City Chapter Board of Trustees  
The Marge & Charles J. Schott Foundation*  
Clyde S. McGregor & LeAnn Pedersen-Pope in memory of Joan Kowing McGregor  
Mercedes Benz  
Merchandise Pickup Service, Inc.  
Missouri Foundation for Health*  
Onyx Pharmaceuticals, Inc.  
The Pamela B. Katten Memorial Leukemia Research Foundation  
PhRMA  
Donald I. Porteous  
PwC  
Nancy C. & Richard Rogers  
Sarah Cannon  
Blood Cancer Network  
Stephen Scherr  
Silicon Valley Bank  
Spice TV  
Daneen & Charles Stiefel  
TIAA-CREF  
Toyota  
Vistar  
VITAS Innovative Hospice Care  
Walgreens  
Gloria, Ellie & Mark Weissberg  
Anonymous (1)

**CHAMPION $300,000 – $999,999**

Ethel & Bernard Gari*  
Kathryn & Rush Limbaugh  
Michael Gari Fund for Leukemia Research at the Dana-Farber Cancer Institute  
PVH  
Team Charles Esten  
Teva Pharmaceuticals  
Anonymous (3)

**PHARMACEUTICAL FUNDING LEGEND**

- Patient Services  
- Public Policy  
- Research  
- Campaign  

* Denotes multi-year commitment
Andrew Brock  
Brant Bukowsky  
Jeff Burch - Hot Ticket Racing  
Caisse de bienfaisance des employés et retraités du CN  
Anthony Campbell  
Matthew Campbell  
Capitol File Magazine  
Carlos Batista Foundation  
CBRE - New England  
CFACQ  
Charity Buzz  
Chiaromonte Construction Company  
Circle City Foundation  
Kathy & Patrick Cocherl  
Color Me Rad Races  
Comcast  
Comedy Central  
Commerce Bank  
Community Health Charities of Kansas & Missouri  
Community Health Charities of Minnesota  
Cranefund for Widows and Children  
Dana-Farber Cancer Institute  
Deutsche Bank  
Samantha & Timothy Durst  
EBAY  
Edward G. & Kathryn E. Mader Foundation  
Family & Friends of Bebe Fineman  
Florentine R. Camenish Trust  
Cristina Muñoz Flores  
Franklin American Mortgage Company  
Piera Freitag  
Furniture Fair  
Vicky Garcia & Carol Alexander  
Generac Power Systems, Inc.  
General Dynamics Information Technology  
Gila River Casinos  
GovPlace  
Grace Heritage Corporation - Newell Foundation  
The Greater Milwaukee Foundation, Inc.  
Jeff Gusing  
Harry Harrison & Amy Nauikas  
Sharon Hathaway  
The HEADstrong Foundation  
HealthyFit  
Al G. Hill, Jr.  
Ken Hitz  
Honored Hero Run  
Houlihan Lawrence  
ICAP Services North America, LLC  
Independent Health  
InfoReliance Corporation  
InquisIT  
J & J Development, Inc.  
J.T. Tai & Co Foundation, Inc.  
Amie & Tony James  
The Jim Jacobs Charitable Foundation  
Kaiser Permanente  
Aileen Kass  
KBR, Inc.  
Kent’s Run  
Kenworth Hazmat  
Kmart Puerto Rico  
Dave Labuda  
Don C. & Diane S. Lake Family  
Left Hand Brewing Foundation  
Leon Medical Centers  
Lilly USA, LLC  
The Lintner Foundation  
The Lipstein Family Foundation  
Lunardi’s Supermarket, Inc.  
Lundbeck Canada  
Madison Classic  
Magid Family Fund  
Pat & Lou Manzi  
Electra & Bruce Martin  
Roxanne & Rocco Martino  
Maxim Group LLC  
Mayo Foundation for Medical Information and Research  
Medimmune, LLC  
Melrynder Foundation  
The Memorial Foundation, Inc.  
Menkes Charity Golf Classic  
Mercedes Benz of Fresno  
Michael C. Fina  
Michael Marks Family Foundation  
Miles & Stockbridge  
NAIOP Chicago  
NetJets  
Newcap, Inc.  
Northrop Grumman  
Northside Hospital Cancer Institute  
Norton Rose Fullbright  
Lynne & Greg O’Brien  
Offshore Sailing School  
OHSU  
Orden, Berkett, Flesh & Sassoover Families  
Penny Packer  
Peoples Natural Gas  
PFG / Vistar  
Philadelphia Multiple Myeloma Networking Group  
Reliant, an NRG Company  
Rhuilen Rock Hill Run & Ramble  
JR Rickert  
Riemer & Braunstein LLP  
Roche Canada  
Roditi Family Fund  
ROMA Charitable Foundation  
RPA Advisors LLC  
SAIC  
Sailing World/Cruising World Magazines  
SanDisk Corporation  
Mr. & Mrs. John F. Scarpa  
Scott Safety  
Charlie Sheen  
Silicon Valley Community Foundation  
Marilyn & Jim Simons  
Elaine S. Smith  
Bonnie & Stephen Spiegle  
St. Joseph’s/Candler  
Noa Staryk  
Mona Carlson Stogner & Grey Stogner  
Symantec Corporation  
Team Telus Cares  
Ted Britt Automotive Group  
Judy & Michael H. Thomas  
Mr. & Mrs. Donald Trump  
Ultimate Software  
Valero Energy Corporation  
VCU Medical Center  
Betty Vest  
Viacom, Inc.  
Virginia Sheldon Jerome Foundation  
Wallace H. Coulter Foundation  
WASH-FM  
Washington Business Journal  
West New York Restoration of CT, Inc.  
Sally & Geoffrey White  
William Rich Foundation  
Willis Foundation  
World Wide Technology, Inc.  
WTOP Radio  
Stanley Zax  
Anonymous (8)
Alice Ann Bien Foundation  
Alliance Data Systems, Inc.  
Allied Capital & Development of South Florida  
Allmond & Company LLC  
The Altschul Foundation - Reichman Memorial  
Alvin J. Siteman Cancer Center  
Ambit Energy  
American Direct Marketing Resources, LLC  
American Electric Systems  
American Endowment Foundation  
American Family Care  
America’s Charities  
Amgen  
Anning Johnson & H&D  
Anadarko Petroleum Corporation  
Anning Johnson & H&D Mechanical  
Anthem Blue Cross & Blue Shield  
Apollo Hospitals  
Ares Management & Adler Realty Services  
ARIAD Pharmaceuticals, Inc.  
Kate & Charles Arnold  
Assurant Foundation  
Assurant Specialty Property  
Astellas Pharma US, Inc.  
Astex Pharma US, Inc.  
Augusta Oncology Associates  
AutoTrader.com  
Arlen Avanessians  
Avella Specialty Pharmacy  
Avnet  
Sine & John Ayres  
Mr. & Mrs. Michael Azeez  
Anna & Dean Backer  
BAE Systems  
George Baker  
Bank of America Merrill Lynch  
Banner MD Anderson Cancer Center  
The Baratta Family Fund  
Barbara & William Rosenthal Family Foundation  
Nonnie & John Barbey  
Barclaycard US  
Michael Bartschat  
The Batchelor Foundation, Inc.  
BB L Construction Services  
BD Biosciences  
Becky & Lewis Brunswick Fund  
Belvedere Cove Foundation & Cromar Foundation  
Ben Carter Enterprises  
Adam Bence  
Bender Foundation  
Mary & Jorge Benitez  
Johanna Berkman & Manny Weintraub  
Berkshire Bank  
Bernadette Schaeffler Collection  
Jason Bice  
Alexandra Mayes Birmbaum  
Bisnow  
BJC HealthCare  
Black Dog Charity  
Blue Buffalo Foundation for Cancer Research  
Blue Canopy  
Blue Cross  
Blue Cross and Blue Shield of Mississippi  
Blumenfeld Development Group  
Susan & Ed Blumenfeld  
BMV of San Antonio  
Michele Boal  
Boehringer Ingelheim Pharmaceuticals, Inc.  
Bogner and Company, Inc.  
Bonadelle Neighborhoods  
Elizabeth & Bruce Bowen  
Gerry & John Boyle  
Brampton Minor Baseball, Inc.  
Brandywine Realty Trust  
Brewers of Indiana Guild  
The Briad Group  
Faye C. Briggs  
Brooks-Mathews Foundation  
Brown & Gould  
Frona A. Brown, Ed.D.  
Reginald Brown  
Daniel Bruckner  
Larry Buchalter  
BuildASign.com  
James Burgin  
Laurie Burns  
Burrt Orange Benefit  
Michael Burrage  
Butler Family Foundation  
Laura & John Byrd  
C. Jay Moorhead Foundation  
David Byrd  
Buttars & Callow Family  
Calvert Foundation  
Dillon Cameron  
Michael Campbell  
Capital One Bank  
Nick Caporella  
Capstone Advisory Group, LLC  
Carbide Concepts Company LLC  
Cardinal Solutions Group, LLC  
CARFAX  
Dana & David Carlos  
Carnival Cruise  
Carol Lavin Bernick Family Foundation  
Scott Carroll & Erin O’Grady  
Holly & Richard Caserta  
Ben Cassell  
CBIZ  
CBRE  
Celator Pharmaceuticals  
CenterPoint Energy  
CentiMark  
Centro - Charleen’s Angels  
Century Elevator Maintenance Corp.  
Cerner Corporation  
CH2M Hill  
Charles Foundation and Becky Godchaux  
Rhoda & David Chase  
The Cherry Picker Foundation  
Chester Valley Golf Club  
Children’s Hospital & Medical Center  
Mary Kay & John Chlebina  
Justin Chueh  
Church & Dwight Co., Inc.  
Cisco Systems  
Citizens for Carolyn H. Krause  
City Barbeque  
City of Batavia  
Clark Construction Group, LLC  
Clark Family Charitable Fund  
Susan & Jay Clark  
Lonnie & Bobbi Clayton  
Cleary Gottlieb Steen & Hamilton LLP  
Isobel & Bruce Cleland  
Clune Construction Company  
Coach Foundation, Inc.  
Coastal Bank & Trust  
Rhodau Cobb - The Cobb Foundation  
CoBiz Financial  
Bert Cohen  
Lawrence Cohen  
Coldwell Banker Residential Brokerage  
Cole, Scott & Kissane PA.  
The Colonial Group  
Jennifer & David Comar  
Combined Health Agencies  
Margaret Comfort  
Community Foundation of New Jersey  
Community Health Charities of Iowa  
Compatriot Capital  
Comstor  
Michael Conlon  
Robyn & Don Conlon  
Contemporary Electric Services, Inc  
Continental Food Services, Inc  
Continental Food Management, Inc.  
Cook Children’s Health Care System  
Cora and John H. Davis Foundation  
Cortland Finnegan  
Ark 31 Foundation  
The Cottrell Foundation  
Courtney Knight Gaines Foundation, Inc.  
Covington & Burling LLP  
The Cox Family of Brownlee—SK Foundation  
Cracker Barrel  
Amy & Daron Cramer  
Cravath, Swaine & Moore LLP  
Credit Suisse  
Cresa Cares, Inc.  
Crockett Facilities Services, Inc.  
Kevin Cronin  
CrossCountry Consulting  
Cruise Industry Charitable Foundation  
CTIA - The Wireless Association  
CWCapital  
Bill Dagians  
Dallas Stars Foundation  
Carole & Robert Daly  
The Damon Giglio Foundation  
Danaher Corporation  
Danford Foundation  
Julie & Roger Davenport  
David Adams Memorial Fund  
David Gigliotti Legacy Foundation  
David Yurman  
The Davis Family Foundation  
Davis Love Foundation  
Davis Polk & Wardwell  
James H. Davis, PhD, JD  
Dayton Interventional Radiology  
Dayton Outpatient Center  
The de Moya Group, Inc.  
Denotes multi-year commitment
DONORS (continued)

John Eidel
Steve Eisenstadt
El Pomar Foundation
Element Financial Corporation
David Elliott
Embassy of the United Arab Emirates
EMC2
Emergent BioSolutions Inc.
Emerson
EN Engineering
The Enrichment Foundation
Entergy Corporation
Enterprise Holdings Foundation
Enterprise Holdings, Inc.
Enterprise Rent-A-Car
Epic
The Escher Foundation - Doris J.W. Escher, MD
ESPN980
Estridge Family Foundation
EXL
Experian
Express Scripts, Inc.
Faisal Rehman Medicine Professional Corporation
Family of Beth Victor
Fansler Foundation
Kristopher Farmer
FarmerMac
Farmers Underwriters Association
Father Serra Catholic School
Brad Feld
Jim Ferguson
Finish Line Physical Therapy
First American Title Insurance Company
First Coast Honda Dealers
First Service Federal Credit Union
Firstenberg Foundation
Bruce Fletcher
Flexco Fleet Services
Florida Panthers Hockey Club LTD
Flushing Bank
FMC Corporation
Foley & Lardner, LLP
Forest City Ratner Companies
Forevermark
Fossils, Inc.
Fox5
Fred Smith Plumbing & Heating Company
Freedom Financial Group, LLC
The Fresno/Clovis New Car Dealers Association
Elyssa Friedland
Beth & Josh Friedman
Marti & Steven Friedman
Frieze Harley-Davidson
FTI Consulting, Inc.
Fullerton Firefighters Association
Fundación Segarra Boerman e Hijos, Inc.
Enrico S. Gaglioti
GAI Consultants, Inc.
Gamma Murs & Fenetres Internacional, Inc.
GAP Inc.
Israel Garcia
Gartland & Mellina Group
Richard Gartner
Gavin/Solsonese LLC
GE
GE Johnson Construction Company
The Geaton & Joann Dece스arι Family Foundation, Inc.
General Dynamics Advanced Information Systems
General Motors Company
Gensler & Rand
The GEO Group, Inc.
The George F. and Myra Shaskan Foundation, Inc.
George L. Shields Foundation, Inc.
Georgia Power Foundation, Inc.
Georgia Regents University
GetWellNetwork, Inc.
Giant Food
Giants Community Fund
Gibson, Dunn & Crutcher LLP
Darin Gillenwater
GlaxoSmithKline
Global Electronic Technology
Global Prairie
The Gold-Diggers, Inc.
Golden Corral
Goldman Sachs
Goldman Sachs Gives
Mike Goliner
Thomas Goodmanson
Becky & Brett Gordon
Gosling’s Rum
The Grainger Foundation
David Grais
Grant Thornton LLP
Alyson Grasso
Harkins Builders
Tom Harrison - In Loving Memory of Sylvia Morningstar Harrison
Harry C. Moores Foundation
The Harley Company
Lisa & Craig Hawkins
H-E-B
Helen W. Bell Charitable Foundation
The Hellis Foundation
Timothy Henkel
Henry J. Lee Distributors, LLC
Hercules Corp.
The Hershey Company
Hewlett-Packard
HGST
Highstar Capital
the Hill Group
Marcy & Donnie Hill
Hines Interests Limited Partnership
HireStrategy
HITT Contracting, Inc.
Hockey Fights Cancer
Hogan Lovells LLP
HOT 99.5
Houlihan Lokey
Howard Family Foundation
Ben Howard
Hoxworth Blood Center
Hy-Vee, Inc.
IBC Bank
IBM
Gabriel Iglesias
Immucor, Inc.
In Memory of Brendan Kelly
Independence Blue Cross
Ingram Micro
Insulators International Health Hazard Fund
Intevac, Inc.
Iron Bow
ISN Software Corp.
Ivie & Associates, Inc.
J & J Shared Services
J.B. Fuqua Foundation
Ellen Jackson
Janssen Biotech, Inc.
Jared Coones Pumpkin Run
Jazz Pharmaceuticals plc.
JDP Mechanical, Inc.
Jeanette & H. Peter Kriendler Charitable Trust
Richard Jeanneret
Jefferies & Company, Inc.
Jewish Community Foundation of the West
The JIAN Group, LLC
The Jim Quay Memorial Fund
Joan C. Ray Charitable Foundation
Gary Jobson - Jobson Sailing
Jochum-Moll Foundation
John & Mary Franklin Foundation
DONORS (continued)

The Phase Foundation
Thomas Phlipbrick
The Phyllis M. Coors Foundation
Pillsbury Winthrop Shaw Pittman LLP
Pimco
Plaid Pantries, Inc.
Planet of Peace
Julie & Marc Platt and Family
PNC Bank
PNC Real Estate
Polk Brothers Foundation
Polsinelli PC
Popeyes Louisiana Kitchen, Inc.
Popular Community Bank
Port Tampa Bay
The Portmann Family Charitable Fund
Powell Industries
Power Services, Inc.
Preferred Health Professionals
Presidio
Monika & John W. Preston
Pretty Sweet Bake Sale
The Prince Henry Charitable Foundation
and Dan Anglin
PRGX USA, Inc.
Price Chopper Supermarkets
Linda & Dr. Steve Priddy
Priority Physicians
Proof of the Pudding
The Pumping Station
Quintiles
Rabobank
Rahr Malting Co.
Hunter from The Rainbow Bridge
Steven Rainey
The Randy and Deborah Daniel Family Charitable Foundation
Paul Raphael
Mary Virginia Rawe
Ray Catena Auto Group
Real Estate One Foundation
Red Robin Lehigh Valley Restaurant Group
Reece Holbrook Win Anyway Foundation, Inc.
Constance M. Reed
Kyle Reed
Mark Regante
The James H. Reid, Jr. Family
Bobbi & Robert Reitzes
Reliance Trust
Reilant Energy Charitable Foundation
Republic National Distributing Company, LLC
James Resnick
Rhodes Computer Services
Jeff Rich—Plum Tree Partners
Richard M. Powell Foundation
Michael J. Richman
Cynthia & Steven Rigby
John Rigney
RMD Corporation—Hooters
The Robert H. Lyon Leukemia Foundation
Ruth Robinson
The Roderick Seward, Flossie Radcliffe & Helen M. Galloway Foundation
Rogers Family Foundation
Lynn & Peter Rogers
Victoria Rogers
Mishel & Greg Rohl
The Romulus T. Weatherman Memorial Fund
Rope for Hope
Royals Charities Fund
Rye YMCA
S&S Ventures
Jeffrey D. Sachs
Pat & Jeff Sachs
SAFE Credit Union
Safeway Inc.
Lauren & John Salata
Joseph Salley
Beth Sailer
Harvey Saltzman
Irvin Saltzman
Sharon & Larry Saltzman
Sam’s Club
Samuel J. Cantor Foundation
San Jose Earthquakes Community Fund
San Manuel Band of Mission Indians
San Par Golf Tournament
Sanofi-Aventis U.S. LLC
SAP America, Inc.
SAP NS2/Carahsoft
Vivian Sasaki
Mr. & Mrs. Richard Schmeik
Scott Schweighauser
Barbara Scotti & Ronald Duval
Sedano’s Supermarkets
Sempra Employee Giving Network
Sempra Energy Foundation
Sereno Group Real Estate
ServiceSource
Sessions, Fishman, Nathan & Israel, LLC
Carl Sewell
Shade Tree Service Company
Shearman & Sterling LLP
Ira Sherman
Sherrard Kuzz LLP
The Shin Foundation
Shiseido Group USA
Vijay & Ram Shriram
Sidley Austin LLP
The Sidney, Milton and Leoma Simon Foundation
Julie E. Silcock
Gil Simonetti III
Neil Simpkins
Lynda & Richard Sirota
Skadden Arps Slate Meagher & Flom LLP
Skanska USA Building, Inc.
Skoloff & Wolfe P.C.
The Sleep Family
Slice of Lime Foundation
Phyllis & Douglas A. Smith
SMW Trading Company, Inc.
So Long to Leukemia
Solstice Benefits, Inc.
Southeast Nebraska Cancer Center
Span-America Medical Systems
Paul Sparks
Mark & Carol Spisak
SproutLoud Media Networks, LLC
SRA International
St. Luke’s Mountain States Tumor Institute
The Stanford C. and Mary Claire Finney Foundation
Stanley Korshak
State Street Corporation
Jerre Stead
Phil Steel
Donald Steiner
Sterne, Kessler, Goldstein & Fox P.L.L.C.
Barbara Stiefel
Stifel
Stone Bridge Iron & Steel, Inc.
Stonebridge Companies
Studley
Pam & Patrick Sullivan
SunTrust Bank
SureTec
Sutter Health Sacramento Sierra Region
SW Challenge
Elizabeth & Michael Sweeney
Lisa Marie Sylvia and Mark L. Heleen
SYNNEX Corporation
Sysmex America, Inc.
Take a Swim Against Cancer-Bucks County Aquatic Swim Teams
Tap Out Cancer, Inc.
TCDI
TD Bank
Team Annie Rose Foundation
Team Chad Foundation
Team Graham, Inc.
Team Chad Foundation
Team Annie Rose Foundation
TDI
Tigeright Foundation
TimeSaver Food Stores Co.
Tishman Speyer
Tishman, an AECOM Company
Title Associates
TJX Companies, Inc.
TM Crowley & Associates
Alfred Tobin
Trayer’s Troops
Trident Case
Trion Group, Inc.
Angela & Gary Trovato
True North Family Foundation
truencore
Trust Company of the South
Jane & Robert Tschudy
Tube City IMS
Renee Twersky
Michael Twyman
UBS Financial Services
UNC Rex Healthcare
Union First Market Bank
United Cancer Research Society
United States Marine, Inc.
United Way of Wyoming Valley
Texas Instruments
Texas Neurosciences Institute
The Inc.
Théâtre Saint-Bruno Players
The Thomas and Agnes Carvel Foundation
Thompson Coburn
Thompson, Habib & Denison, Inc.
Mary Thompson
Thoroughbred Title Services
Tiber Creek Partners, LLC
Tigeright Foundation
TimeSaver Food Stores Co.
Tishman Speyer
Tishman, an AECOM Company
Title Associates
TJX Companies, Inc.
TM Crowley & Associates
Alfred Tobin
Trayer’s Troops
Trident Case
Trion Group, Inc.
Angela & Gary Trovato
True North Family Foundation
truencore
Trust Company of the South
Jane & Robert Tschudy
Tube City IMS
Renee Twersky
Michael Twyman
UBS Financial Services
UNC Rex Healthcare
Union First Market Bank
United Cancer Research Society
United States Marine, Inc.
United Way of Wyoming Valley
### Top Campaign Fundraisers

<table>
<thead>
<tr>
<th>Name</th>
<th>Company/Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julie Boyd</td>
<td>Bristol-Meyers Squibb Company</td>
</tr>
<tr>
<td>Jill Broering</td>
<td>Abbey Brockman</td>
</tr>
<tr>
<td>James Brandell</td>
<td>Jennifer Butto</td>
</tr>
<tr>
<td>Robert “Spider” Cantley</td>
<td>Michael Caputo</td>
</tr>
<tr>
<td>Laurie Adami &amp; Laurie’s Warriors</td>
<td>Susan Caron</td>
</tr>
<tr>
<td>Chasity Adkisson</td>
<td>Donal L. Carter, Jr.</td>
</tr>
<tr>
<td>ADP</td>
<td>Carter’s Inc.</td>
</tr>
<tr>
<td>Anjou Aihborn</td>
<td>Jessica Catlin</td>
</tr>
<tr>
<td>Yvette A. Aleman, P.E.</td>
<td>Deborah Christine</td>
</tr>
<tr>
<td>Alex and Ani</td>
<td>Brenda Cioce</td>
</tr>
<tr>
<td>Brian Allain</td>
<td>Ryan J. Claxton</td>
</tr>
<tr>
<td>Timothy Allen</td>
<td>Whitney Cohn</td>
</tr>
<tr>
<td>David Altman</td>
<td>Amy Cohen &amp; Team Amy</td>
</tr>
<tr>
<td>Vivian Altman</td>
<td>Steve Collins</td>
</tr>
<tr>
<td>Elena Alvarez, MD</td>
<td>Colton’s Army</td>
</tr>
<tr>
<td>Jim A. Anderson, Jr.</td>
<td>Derek Copeland</td>
</tr>
<tr>
<td>Charles Arnold</td>
<td>Catherine Courage</td>
</tr>
<tr>
<td>Ren Arrogante</td>
<td>Dr. Ed Crane</td>
</tr>
<tr>
<td>Astellas USA Foundation</td>
<td>Crenshaw Team</td>
</tr>
<tr>
<td>Austaco, LTD</td>
<td>Nathan M. Crowley</td>
</tr>
<tr>
<td>Damian Bailey</td>
<td>Randy Cubriel</td>
</tr>
<tr>
<td>Jamie Baker</td>
<td>Dr. Jennifer Cultera</td>
</tr>
<tr>
<td>Baker Botts L.L.P.</td>
<td>Lyndsey Danberry</td>
</tr>
<tr>
<td>Baptist Health South Florida</td>
<td>Amy Cohen</td>
</tr>
<tr>
<td>Barcays</td>
<td>Team Amy</td>
</tr>
<tr>
<td>Christopher Barnes</td>
<td>Steve Collins</td>
</tr>
<tr>
<td>Mark Barsotti</td>
<td>Colton’s Army</td>
</tr>
<tr>
<td>BDO</td>
<td>Derek Copeland</td>
</tr>
<tr>
<td>Dr. Matthew Beldner - Team Beldner</td>
<td>Catherine Courage</td>
</tr>
<tr>
<td>Jim Biltz</td>
<td>Dr. Ed Crane</td>
</tr>
<tr>
<td>Dr. Gregiore Bergier</td>
<td>Crenshaw Team</td>
</tr>
<tr>
<td>Rose Bevilacqua</td>
<td>Nathan M. Crowley</td>
</tr>
<tr>
<td>Katie Biehl</td>
<td>Randy Cubriel</td>
</tr>
<tr>
<td>The Blackstone Group</td>
<td>Dr. Jennifer Cultera</td>
</tr>
<tr>
<td>Brad Blumenfeld</td>
<td>Lyndsey Danberry</td>
</tr>
<tr>
<td>BMC</td>
<td>Amy Cohen</td>
</tr>
<tr>
<td>Bianca Bonadelle</td>
<td>Team Amy</td>
</tr>
<tr>
<td>Suzanne Bourque</td>
<td>Steve Collins</td>
</tr>
<tr>
<td>Mark G. Weinstein</td>
<td>Colton’s Army</td>
</tr>
<tr>
<td>Welden Service &amp; Repair</td>
<td>Derek Copeland</td>
</tr>
<tr>
<td>The Weiler Foundation</td>
<td>Catherine Courage</td>
</tr>
<tr>
<td>Shari &amp; Marc Weissbach</td>
<td>Dr. Ed Crane</td>
</tr>
<tr>
<td>Wells Fargo Foundation</td>
<td>Crenshaw Team</td>
</tr>
<tr>
<td>Marvin Wenger</td>
<td>Nathan M. Crowley</td>
</tr>
<tr>
<td>West Marine</td>
<td>Randy Cubriel</td>
</tr>
<tr>
<td>Western Refining, Inc.</td>
<td>Dr. Jennifer Cultera</td>
</tr>
<tr>
<td>Wet Willie’s Management Corp.</td>
<td>Lyndsey Danberry</td>
</tr>
<tr>
<td>White Castle</td>
<td>Amy Cohen</td>
</tr>
<tr>
<td>Kenneth Whitney</td>
<td>Team Amy</td>
</tr>
<tr>
<td>Wicker, Smith, O’Hara, McCoy &amp; Ford, PA.</td>
<td>Steve Collins</td>
</tr>
<tr>
<td>Wallace Williams</td>
<td>Colton’s Army</td>
</tr>
<tr>
<td>Williams-Corbett Foundation</td>
<td>Derek Copeland</td>
</tr>
<tr>
<td>Willis Auto Campus</td>
<td>Catherine Courage</td>
</tr>
<tr>
<td>Winsboro Petroleum Company</td>
<td>Dr. Ed Crane</td>
</tr>
<tr>
<td>Winston &amp; Strawn LLP</td>
<td>Crenshaw Team</td>
</tr>
<tr>
<td>The Witkoff Group</td>
<td>Nathan M. Crowley</td>
</tr>
<tr>
<td>WVB-TV, Channel 4/CW 23</td>
<td>Randy Cubriel</td>
</tr>
<tr>
<td>WMZQ</td>
<td>Dr. Jennifer Cultera</td>
</tr>
<tr>
<td>Wombok Caryle Sandridge &amp; Rice, LLP</td>
<td>Lyndsey Danberry</td>
</tr>
<tr>
<td>Wombole Company, Inc.</td>
<td>Amy Cohen</td>
</tr>
<tr>
<td>Woodbridge Bowl</td>
<td>Team Amy</td>
</tr>
<tr>
<td>WR Starkey Mortgage, LLP</td>
<td>Steve Collins</td>
</tr>
<tr>
<td>WTS, Inc.</td>
<td>Colton’s Army</td>
</tr>
<tr>
<td><a href="http://www.lovealwaysfund.org.in">www.lovealwaysfund.org.in</a></td>
<td>Derek Copeland</td>
</tr>
<tr>
<td>in memory of Emily Schuetz Stryker</td>
<td>Catherine Courage</td>
</tr>
<tr>
<td>Eric, Tamara and Nicholas Yollick</td>
<td>Dr. Ed Crane</td>
</tr>
<tr>
<td>Yvonne &amp; Tamer Youssef</td>
<td>Crenshaw Team</td>
</tr>
<tr>
<td>Cathy &amp; Scott Zeilinger</td>
<td>Nathan M. Crowley</td>
</tr>
<tr>
<td>Ziolkowski Patent Solutions Group</td>
<td>Randy Cubriel</td>
</tr>
<tr>
<td>Joseph Zvesper</td>
<td>Dr. Jennifer Cultera</td>
</tr>
<tr>
<td>Anonymous (23)</td>
<td>Lyndsey Danberry</td>
</tr>
<tr>
<td></td>
<td>Amy Cohen</td>
</tr>
<tr>
<td></td>
<td>Team Amy</td>
</tr>
<tr>
<td></td>
<td>Steve Collins</td>
</tr>
<tr>
<td></td>
<td>Colton’s Army</td>
</tr>
</tbody>
</table>

**Schools that have raised more than $25,000, individuals who have raised more than $50,000 or companies/teams that have raised more than $100,000 to support LLS’s mission.**

1. †† Denotes multi-year commitment

---

*Note: The list includes a variety of companies, foundations, and organizations that have contributed to LLS's mission.*
DONORS (continued)

MaggieMoo’s Ice Cream & Treatery
Lucky Mahi
Gina Manos
Marble Slab Creamery
Suzanne Marse Bourque
Nicholas Mastroianni, III
Ryan McDade
Brenda McCarthy
Dan McCarthy
Kathy McCauslin-Cadieux
Danny McGeady
Kathy McCauslin-Cadieux
Danny McGeady
Kathy McCauslin-Cadieux
Lucky Malhi
MaggieMoo’s Ice Cream & Treatery

MWOY Leadership Team
National Capital Area Chapter
NARS
Cristina Muñoz
Casey Munck
Gary Moy
Cheryl Mosley
Gary Moy

National Capital Area Chapter
MWOY Leadership Team
Nadder Nejad
Jennifer Nelson Williams
Grace Ng
Kae Lynne Nelson
Eric North
Linda Norton
Blair Nottingham
Novartis Pharmaceuticals Corporation
Adam Noyes SVF of Proof of the Pudding’s Hospitality for Hope Campaign
Lynne O’Brien
Todd Oakes
Jan Ochocki
Richard Ojeda
Onyx Pharmaceuticals, Inc.
David Osborn
Gwen Ottenberg
Stacie Oxman
Mark Pahl - Team (R)Andy Michael Parrish
Partners For A Cure
Justus Paschal
Alex Perdikis
Elena Peroulakis
Mark Peterson
Phizer Inc.
Pharmaceuticals/Janssen
Pharmaceutical Companies
Justine M. Phillips, Esq.
Mandy Pilgrim
Becca Pluizza
Ryan Plantz - Team Insure A Cure
Lynn Polizos
Pretzelmaker
Dr. Matthew Priddy
Larry Provo
Jason Putorti
PVH
PwC
John Ragan
Rampart High School
Greg Rankich
Gray Reed
Riders of the Storm
Jacob Robinson & Team K.O.
Corey M. Roblee
Jennifer Rogers & Robert Carlock Melanie Romanaux Jose C. Romano Carrie Ronan Sondra Rose Brewer Rowe Benjamin Rubenstein Ryan’s Light
Salesforce.com
Dr. Larry Saltzman
Paula Sanchez
Tony Sanchez
SanDisk Corporation
Sarah Cannon Blood Cancer Network
Fuad Sawaya
Col. Donald Schaut USMCR (retired)
Rick Schueller
Scott Schweighauser
Zachary Scott
Liz Scudillo & Team Two Sisters
Joel Seleskie
Tom Sessi
Nikolas Siggias
Neal Shah
Kris Shanahan
David Shapiro
Kandice Sheehan Fergus
JoAnn Shaw
Lance Shaw
Kandice Sheehan
Sonu Singhvi
Robert Singley
Leah Siocum
Evelyn Smallwood
Ashley Smith
Dana Smith
Kya Smith
Blair Smithcamp
John Sorrentino
Spectrum Pharmaceuticals
Alex Stamias
Stater Bros. Charities
Nick Stefanakis
Stewart School
Deidre Strunk
Glenn Sullivan
Mary Sullivan
Rebecca Sweet

Hasti Taghi
Team Blumenfeld & Waterman
Team Carl
Team Dezma
Team Doug - Lois Kroll
Team Gary
Team Honored Hero
Team Hope
Team Hunter
Team Jay
Team Laura
Team LV
Team LOL
Team Mickey
Team PhRMA
Team Reese
Team Ryan
Team Skinner - RAAM 2014
Team Stephanie
Team Stronger Than You Think
Team Today - Dr. Christina Velt & Reina Sinni
Team Virginia
Terumo BCT
Lee Tesser
Teva Oncology
Kim Tindall††
Katie Tipper-McWhorter
Lona Tod
Mark Torelo
Greg Trayer

UBS Financial Services, Inc.
United for the Cure
Jim Verdi - Team Hardcore for a Cure
Vistar
VITAS Innovative Hospice Care
Waddell & Reed
Walgreens
Vanessa Walker
Walt Whitman High School
Walter Johnson High School
Karen Warner
Washington Gas
Krystle Waters
Watertown Middle School
Carly Watts
Wells Fargo
DebJo Wheatley
Suzy Whittenton
Sarah Wilbur
William Mason High School
Chris Wilso & We Will Find a Cure
Samara Wolfe & the Wolfe Family††
The Womble Bulldogs

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.

LEGACY CIRCLE

Jared Brancazio
Barbara Brunell
Sandra Backus
Patrick Bianchi*
Thomas Blackman*
Edith Blankenship
Lorie Coon*
David and Carol Cooper
Joy Cowan
Ida Daly*
Kenneth Dawson*
Frederick Dibble*
Allan Ecker*
Daniel Feldt
Lawrence and Piera Freitag
Dennis Gerin*
Charles Gibbs*
Barbara Gol
Joyce L. Holl
Joseph Ignatowski
Edith Ingram
William Jackson*
Patricia Johnson
Louise B. Judson
Diane Kalliam
Bonnie Kallenborn*
Beth Kissling
Jamie Klingman
Melvin Kraemer
Wallace Blaine Lawrence
Edward and Alice Lehtinen*
Helen Lippert*
Janet Martin*
Tim and Jane McKay
Jane Metzger*
Rose Morrissey*
Mary Jean Neal*
Annabel Neff*
Jeffrey and Paula Nelson
Alan R. Propst*
Kyle and Monica Roderick
Rose Rodriguez*
Winnifrith Roman*
Charles Rose*
Julie Roth*
Angela Ryan*
John Seijun Sato*
Elmo and Dolores Schmid
Norma Scott*
Bruno and Irma Selmi*
Elisabeth Situm*
Alfred Skeneay
Georgette Skellenger*

Steven W.L. Solana
David and Jeanette Stevens
William Stockert*
Bruce Swartz*
Scott A. Thomas
Diego Tobon*
Ely Susan Valas
Sarah Walters*
Estella Ruth Watts*
Beth Weigand
Anonymous (8)

* Deceased
†† National Man & Woman of the Year
All Star Alumni
INDEPENDENT AUDITORS’ REPORT

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2014, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements: Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ Responsibility: Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion: In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2014, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Report on Summarized Comparative Information: We have previously audited LLS’s consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated September 18, 2013. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2013 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

October 15, 2014
### CONSOLIDATED BALANCE SHEET

**The Leukemia & Lymphoma Society, Inc. / June 30, 2014 (With comparative amounts at June 30, 2013) (In thousands)**

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and cash equivalents (note 6)</td>
<td>$28,771</td>
<td>$27,300</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>5,362</td>
<td>5,555</td>
</tr>
<tr>
<td>Legacies and contributions receivable, net (note 5)</td>
<td>9,113</td>
<td>8,026</td>
</tr>
<tr>
<td>Investments (notes 3 and 6)</td>
<td>188,885</td>
<td>190,555</td>
</tr>
<tr>
<td>Fixed assets, net (note 7)</td>
<td>16,604</td>
<td>10,853</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$248,735</strong></td>
<td><strong>242,289</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Liabilities and Net Assets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$20,685</td>
<td>21,388</td>
</tr>
<tr>
<td>Deferred revenue (note 6)</td>
<td>26,745</td>
<td>35,074</td>
</tr>
<tr>
<td>Awards and grants payable (note 2)</td>
<td>84,201</td>
<td>74,825</td>
</tr>
<tr>
<td>Co-Pay assistance payable (note 2)</td>
<td>16,698</td>
<td>7,237</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>148,329</strong></td>
<td><strong>138,524</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commitments and contingencies (notes 2 and 9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net assets (note 4):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>68,842</td>
<td>91,217</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>27,989</td>
<td>9,105</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,575</td>
<td>3,443</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>100,406</strong></td>
<td><strong>103,765</strong></td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$248,735</strong></td>
<td><strong>242,289</strong></td>
</tr>
</tbody>
</table>

*See accompanying notes to consolidated financial statements.*
# CONSOLIDATED STATEMENT OF ACTIVITIES

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2014 (With summarized totals for the year ended June 30, 2013) (In thousands)

## Operating Revenue

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2014</th>
<th>Total 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$250,433</td>
<td>20,654</td>
<td>—</td>
<td>271,087</td>
<td>276,098</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(28,784)</td>
<td>0</td>
<td>0</td>
<td>(28,784)</td>
<td>(35,510)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>221,649</td>
<td>20,654</td>
<td>—</td>
<td>242,303</td>
<td>240,588</td>
</tr>
<tr>
<td>Co-pay contributions</td>
<td>—</td>
<td>67,100</td>
<td>—</td>
<td>67,100</td>
<td>48,143</td>
</tr>
<tr>
<td>Legacies</td>
<td>4,050</td>
<td>1,505</td>
<td>—</td>
<td>5,555</td>
<td>4,226</td>
</tr>
<tr>
<td>Donated services and media (note 6)</td>
<td>10,985</td>
<td>—</td>
<td>—</td>
<td>10,985</td>
<td>7,750</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>1,365</td>
<td>44</td>
<td>79</td>
<td>1,488</td>
<td>2,075</td>
</tr>
<tr>
<td>Net assets released from restrictions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>55,393</td>
<td>(55,393)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>15,239</td>
<td>(15,239)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Total operating revenue</td>
<td>308,681</td>
<td>18,671</td>
<td>79</td>
<td>327,431</td>
<td>302,782</td>
</tr>
</tbody>
</table>

## Operating Expenses (note 10)

### Program services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2014</th>
<th>Total 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>85,034</td>
<td>—</td>
<td>—</td>
<td>85,034</td>
<td>76,494</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>104,170</td>
<td>—</td>
<td>—</td>
<td>104,170</td>
<td>104,830</td>
</tr>
<tr>
<td>Public health education</td>
<td>47,585</td>
<td>—</td>
<td>—</td>
<td>47,585</td>
<td>46,080</td>
</tr>
<tr>
<td>Professional education</td>
<td>19,656</td>
<td>—</td>
<td>—</td>
<td>19,656</td>
<td>20,729</td>
</tr>
<tr>
<td>Total program services</td>
<td>256,445</td>
<td>—</td>
<td>—</td>
<td>256,445</td>
<td>248,133</td>
</tr>
</tbody>
</table>

### Supporting services:

<table>
<thead>
<tr>
<th></th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2014</th>
<th>Total 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management and general</td>
<td>28,734</td>
<td>—</td>
<td>—</td>
<td>28,734</td>
<td>28,009</td>
</tr>
<tr>
<td>Fund raising</td>
<td>54,353</td>
<td>—</td>
<td>—</td>
<td>54,353</td>
<td>49,620</td>
</tr>
<tr>
<td>Total supporting services</td>
<td>83,087</td>
<td>—</td>
<td>—</td>
<td>83,087</td>
<td>77,629</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>339,532</td>
<td>—</td>
<td>—</td>
<td>339,532</td>
<td>325,762</td>
</tr>
</tbody>
</table>

## Change in net assets from operating activities

<table>
<thead>
<tr>
<th></th>
<th>Total 2014</th>
<th>Total 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets from operating activities</td>
<td>(30,851)</td>
<td>(22,980)</td>
</tr>
<tr>
<td>Write off of contribution receivable (note 5)</td>
<td>(3,507)</td>
<td>—</td>
</tr>
<tr>
<td>Foreign currency translation adjustment</td>
<td>(153)</td>
<td>(84)</td>
</tr>
<tr>
<td>Net increase in fair value of investments (note 3)</td>
<td>12,136</td>
<td>12,402</td>
</tr>
<tr>
<td>Change in net assets</td>
<td>(22,375)</td>
<td>(13,375)</td>
</tr>
</tbody>
</table>

## Net Assets

<table>
<thead>
<tr>
<th></th>
<th>Total 2014</th>
<th>Total 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>91,217</td>
<td>103,765</td>
</tr>
<tr>
<td>End of year</td>
<td>$ 68,842</td>
<td>103,765</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2014 (With comparative totals for the year ended June 30, 2013) (In thousands)

### Program Services

<table>
<thead>
<tr>
<th>Research</th>
<th>Patient and community service</th>
<th>Public health education</th>
<th>Professional education</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>$63,716</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>63,716</td>
</tr>
<tr>
<td>16,107</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>16,107</td>
</tr>
<tr>
<td>—</td>
<td>2,524</td>
<td>—</td>
<td>—</td>
<td>2,524</td>
</tr>
<tr>
<td>—</td>
<td>49,246</td>
<td>—</td>
<td>—</td>
<td>49,246</td>
</tr>
<tr>
<td>67</td>
<td>1,159</td>
<td>748</td>
<td>329</td>
<td>2,303</td>
</tr>
<tr>
<td>1,128</td>
<td>3,858</td>
<td>600</td>
<td>—</td>
<td>5,586</td>
</tr>
<tr>
<td>2,591</td>
<td>23,024</td>
<td>20,471</td>
<td>7,451</td>
<td>53,537</td>
</tr>
<tr>
<td>173</td>
<td>5,285</td>
<td>4,920</td>
<td>3,341</td>
<td>13,719</td>
</tr>
<tr>
<td>97</td>
<td>1,667</td>
<td>1,075</td>
<td>473</td>
<td>3,312</td>
</tr>
<tr>
<td>23</td>
<td>2,817</td>
<td>2,293</td>
<td>940</td>
<td>6,073</td>
</tr>
<tr>
<td>2</td>
<td>151</td>
<td>134</td>
<td>148</td>
<td>435</td>
</tr>
<tr>
<td>8</td>
<td>665</td>
<td>725</td>
<td>617</td>
<td>2,015</td>
</tr>
<tr>
<td>124</td>
<td>1,728</td>
<td>1,385</td>
<td>469</td>
<td>3,706</td>
</tr>
<tr>
<td>49</td>
<td>2,082</td>
<td>4,968</td>
<td>1,864</td>
<td>8,963</td>
</tr>
<tr>
<td>2</td>
<td>795</td>
<td>696</td>
<td>626</td>
<td>2,119</td>
</tr>
<tr>
<td>2</td>
<td>873</td>
<td>2,989</td>
<td>127</td>
<td>3,991</td>
</tr>
<tr>
<td>602</td>
<td>882</td>
<td>1,307</td>
<td>262</td>
<td>3,053</td>
</tr>
<tr>
<td>340</td>
<td>5,866</td>
<td>3,783</td>
<td>1,666</td>
<td>11,655</td>
</tr>
<tr>
<td>1</td>
<td>1,043</td>
<td>640</td>
<td>292</td>
<td>1,976</td>
</tr>
<tr>
<td>2</td>
<td>505</td>
<td>851</td>
<td>1,051</td>
<td>2,409</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$85,034</strong></td>
<td><strong>104,170</strong></td>
<td><strong>47,585</strong></td>
<td><strong>19,656</strong></td>
</tr>
</tbody>
</table>

### Supporting Services

<table>
<thead>
<tr>
<th>Management and general</th>
<th>Fund raising</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>28,734</td>
<td>54,353</td>
<td>83,087</td>
</tr>
<tr>
<td><strong>Total Supporting Services</strong></td>
<td><strong>24.5%</strong></td>
<td><strong>24.5%</strong></td>
</tr>
</tbody>
</table>

### Total Expenses

| 28,784 | 35,510 |

See accompanying notes to consolidated financial statements.

### EXPENSES

- **Research** 25.0%
- **Patient and Community Service** 30.7%
- **Public Health Education** 14.0%
- **Professional Education** 5.8%
- **Total Program Services** 75.5%
- **Management and General** 8.5%
- **Fund raising** 16.0%
- **Total Supporting Services** 24.5%
- **Total Expenses** 100.0%
<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash flows from operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$  (3,359)</td>
<td>(13,375)</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash (used in) provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net increase in fair value of investments</td>
<td>(12,402)</td>
<td>(9,689)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>3,989</td>
<td>3,050</td>
</tr>
<tr>
<td>Provision for uncollectible accounts</td>
<td>(304)</td>
<td>14</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>193</td>
<td>1,161</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
<td>(783)</td>
<td>(2,627)</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>(703)</td>
<td>1,192</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>(8,329)</td>
<td>17,337</td>
</tr>
<tr>
<td>Awards and grants payable</td>
<td>9,376</td>
<td>6,510</td>
</tr>
<tr>
<td>Co-Pay assistance payable</td>
<td>9,461</td>
<td>1,586</td>
</tr>
<tr>
<td>.Net cash (used in) provided by operating activities</td>
<td>(2,861)</td>
<td>5,159</td>
</tr>
<tr>
<td>Cash flows from investing activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of fixed assets</td>
<td>(9,740)</td>
<td>(7,049)</td>
</tr>
<tr>
<td>Purchases of investments</td>
<td>(77,132)</td>
<td>(54,862)</td>
</tr>
<tr>
<td>Sales of investments</td>
<td>91,204</td>
<td>58,080</td>
</tr>
<tr>
<td>Net cash provided by (used in) investing activities</td>
<td>4,332</td>
<td>(3,831)</td>
</tr>
<tr>
<td>Net increase in cash and cash equivalents</td>
<td>1,471</td>
<td>1,328</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>27,300</td>
<td>25,972</td>
</tr>
<tr>
<td>Cash and cash equivalents at end of year</td>
<td>$ 28,771</td>
<td>27,300</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
1. Organization and Summary of Significant Accounting Policies

Organization
The Leukemia & Lymphoma Society, Inc. (LLS) is the world’s largest voluntary health agency dedicated to finding cures for blood cancers. LLS’s mission is to cure leukemia, lymphoma, Hodgkin’s disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information for blood cancer, education and support, and influences policies that accelerate the development and approval of new blood cancer therapies. LLS advocates for blood cancer patients and their families, helping patients navigate their cancer treatments and ensuring they have access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policymakers at all levels of government.

Tax-Exempt Status
LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS recognizes the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to LLS’s exempt purpose is subject to tax under Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax liability for the years ended June 30, 2014 and 2013.

Principles of Consolidation
The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its fifty-four chapters in the United States, and LLS’s not for profit affiliates, LLSC and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc., and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

Estimates
The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, the allowance for uncollectible accounts, the allocation of expenses, and the valuation of donated services and media. Actual results could differ from those estimates.

Risks and Uncertainties
LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS’s principal source of revenue is amounts contributed by the general public. Accordingly, LLS’s operations are impacted by individual contributions, which are impacted by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2014 and 2013 was funded by six and five donors, respectively.

Summarized Financial Information
The consolidated financial statements are presented with 2013 summarized or comparative information.

With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2013 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2013 consolidated financial statements from which the summarized information was derived.

Subsequent Events
LLS evaluated subsequent events after the balance sheet date of June 30, 2014 through October 15, 2014, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

Net Asset Classifications
To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

- Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.
- Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.
- Permanently restricted net assets: Consist of funds that contain donor imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds are recorded as temporarily restricted net assets and are released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 4).

Foreign Currency Translation
LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency impact of the translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 unobservable inputs for the asset or liability.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The Leukemia & Lymphoma Society, Inc. / June 30, 2014 (With comparative amounts as of and for the year ended June 30, 2013)

LLS follows the provisions of Accounting Standards Codification (ASC) 820, Fair Value Measurement, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers.

Most investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the funds’ underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of LLS’s interest therein, its classification in Level 2 or 3 is based on LLS’s ability to redeem its interest at or near June 30. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

The carrying value of cash and cash equivalents, accounts payable and accrued expenses, and grants payable approximates fair value because of their short-term nature.

Contributions, Grants and Deferred Revenue
Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

Donated Services
LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense.

Donated Media
LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the financial statements, was estimated based on the placement, audience, and demographics of the PSA’s.

Cash Equivalents
Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

Investments
Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

Fixed Assets and Depreciation
Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

Professional Fees
Professional fees included in the consolidated financial statements principally include professional fund-raising fees, contracted software development, and legal and auditing fees.

Reclassifications
Certain reclassifications of 2013 amounts have been made to conform to the 2014 presentation.

2. Research and Co-Pay Assistance Program

LLS has various activities that are utilized to carry out its mission as presented below:

Research:

Awards and Grants: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as revenue when contractual conditions have been satisfied. The budgets for multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi-year grant commitments of $67,590,000 at June 30, 2014 which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $84,201,000 and $74,825,000 at June 30, 2014 and 2013, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately $821,000 and $1,844,000 as of June 30, 2014 and 2013, respectively, have been netted against awards and grants expense.

Therapy Acceleration Program (TAP): TAP is LLS’s strategic initiative to speed the development of blood-cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $28,575,000 and $40,964,000 at June 30, 2014 and 2013, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th>2015</th>
<th>$ 50,448</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2016</td>
<td>30,765</td>
</tr>
<tr>
<td></td>
<td>2017</td>
<td>12,268</td>
</tr>
<tr>
<td>2018 and thereafter</td>
<td></td>
<td>2,684</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>$ 96,165</td>
</tr>
</tbody>
</table>

Co-Pay Assistance Program:
Co-Pay Assistance Program: The Co-Pay Assistance program offers financial assistance to patients in meeting their insurance co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expended in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. Accordingly, LLS has recognized $11,707,000 in temporarily restricted revenue in the current year for which the corresponding expense will not be recognized until the subsequent fiscal year as patients are approved in the program. The Co-Pay Assistance payable of $16,698,000 and $7,237,000 has
been established based on approved patient applications received through June 30, 2014 and 2013, respectively. At June 30, 2014, temporarily restricted net assets include $11,707,000 received in 2014 which are available for expenditure and are intended to be awarded in fiscal 2015.

The following summarizes the activities of the Co-Pay Assistance program in 2014 and 2013.

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant commitments</td>
<td>$67,100</td>
<td>48,143</td>
</tr>
<tr>
<td>Amount expended during the year:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct assistance to patients</td>
<td>(49,246)</td>
<td>(42,650)</td>
</tr>
<tr>
<td>Other expenses incurred and reimbursed under the contract</td>
<td>(6,147)</td>
<td>(5,493)</td>
</tr>
<tr>
<td>Amounts available for expenditures in the next year</td>
<td>$11,707</td>
<td>–</td>
</tr>
</tbody>
</table>

3. Investments

The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2014 and 2013 (in thousands):

<table>
<thead>
<tr>
<th>2014</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$25,633</td>
<td>25,633</td>
<td>–</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income (mutual fund)</td>
<td>55,513</td>
<td>55,513</td>
<td>–</td>
</tr>
<tr>
<td>Short duration fixed income (mutual fund)</td>
<td>33,923</td>
<td>33,923</td>
<td>–</td>
</tr>
<tr>
<td>U.S. Treasury Inflation-Protected Security fund (TIPS) and other</td>
<td>3,431</td>
<td>1,057</td>
<td>2,374</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>5,594</td>
<td>5,594</td>
<td>–</td>
</tr>
<tr>
<td>International equity</td>
<td>6,905</td>
<td>6,905</td>
<td>–</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>1,717</td>
<td>1,717</td>
<td>–</td>
</tr>
<tr>
<td>Alternative investments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multistrategy hedge funds</td>
<td>40,769</td>
<td>–</td>
<td>40,769</td>
</tr>
<tr>
<td>Long/short equities</td>
<td>3,705</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Real assets</td>
<td>8,826</td>
<td>–</td>
<td>8,826</td>
</tr>
<tr>
<td>Limited partnership equity indices</td>
<td>2,869</td>
<td>–</td>
<td>2,869</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$188,885</strong></td>
<td><strong>130,342</strong></td>
<td><strong>54,838</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2013</th>
<th>Level 1</th>
<th>Level 2</th>
<th>Level 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$1,071</td>
<td>1,071</td>
<td>–</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income (mutual fund)</td>
<td>63,003</td>
<td>63,003</td>
<td>–</td>
</tr>
<tr>
<td>Short duration fixed income (mutual fund)</td>
<td>32,316</td>
<td>32,316</td>
<td>–</td>
</tr>
<tr>
<td>U.S. Treasury Inflation-Protected Security fund (TIPS) and other</td>
<td>3,231</td>
<td>940</td>
<td>2,291</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$190,555</strong></td>
<td><strong>115,992</strong></td>
<td><strong>71,205</strong></td>
</tr>
</tbody>
</table>

**Equities:**
- Large cap equity: 6,901
- International equity: 9,739
- Small/mid cap equity: 2,022

**Alternative investments:**
- Multistrategy hedge funds: 58,323
- Long/short equities: 3,538
- Real assets: 8,656
- Limited partnership equity indices: 2,736

Investment expenses of $1,338,000 and $1,301,000 have been netted against the net increase in fair value of investments for the years ended June 30, 2014 and 2013, respectively. The unrealized gains were $6,573,000 and $3,810,000 for the years ended June 30, 2014 and 2013, respectively.

LLS’s alternative investments are diversified across four investment strategies, as follows:

1. **Multi strategy hedge funds**—represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event-driven strategies, distressed debt, merger and other arbitrage, and value investing.

2. **Long/short equities**—primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.

3. **Real asset strategy**—passively managed real asset portfolios comprise Real Estate Investment Trust Index, commodities, and global natural resource stocks.

4. **Limited partnership equity indices**—The underlying holdings of the limited partnership equity indices are principally domestic and international marketable securities.

These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 1 to 95 days. By contrast, all of LLS’s nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2014, the following table summarizes the composition of such alternative investments at fair value by the various redemption provisions (in thousands):

<table>
<thead>
<tr>
<th>Redemption period</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily</td>
<td>$8,826</td>
</tr>
<tr>
<td>Monthly</td>
<td>2,869</td>
</tr>
<tr>
<td>Quarterly</td>
<td>40,769</td>
</tr>
<tr>
<td>Annual</td>
<td>3,705</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$56,169</strong></td>
</tr>
</tbody>
</table>

As of June 30, 2014 and 2013, LLS has no unfunded commitments on its alternative investments.

The following table presents a reconciliation for all Level 3 assets measured at fair value as of June 30, 2014 and 2013 (in thousands):

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance at July 1</td>
<td>$3,358</td>
<td>3,042</td>
</tr>
<tr>
<td>Investment expense</td>
<td>(79)</td>
<td>(79)</td>
</tr>
<tr>
<td>Net increase in fair value</td>
<td>426</td>
<td>395</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$3,705</strong></td>
<td><strong>3,358</strong></td>
</tr>
</tbody>
</table>
## 4. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2014 and 2013 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Time restrictions</td>
<td>1,295</td>
<td>-</td>
<td>992</td>
<td>-</td>
<td>2,287</td>
<td>2,052</td>
</tr>
<tr>
<td>Research</td>
<td>10,724</td>
<td>3,270</td>
<td>5,721</td>
<td>3,201</td>
<td>16,945</td>
<td>16,921</td>
</tr>
<tr>
<td>Patient service</td>
<td>2,802</td>
<td>-</td>
<td>2,126</td>
<td>-</td>
<td>4,928</td>
<td>4,926</td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>11,707</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>11,707</td>
<td>11,707</td>
</tr>
<tr>
<td>Other</td>
<td>1,461</td>
<td>305</td>
<td>266</td>
<td>242</td>
<td>2,027</td>
<td>1,961</td>
</tr>
<tr>
<td>Total</td>
<td>27,989</td>
<td>3,575</td>
<td>9,105</td>
<td>3,443</td>
<td>37,564</td>
<td>33,192</td>
</tr>
</tbody>
</table>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2014 and 2013 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor-restricted endowment funds for the year ended June 30, 2014 and June 30, 2013 (in thousands):

<table>
<thead>
<tr>
<th>Purpose</th>
<th>2014 Less than one year</th>
<th>2014 1 to 5 years</th>
<th>2014 After 5 years</th>
<th>2013 Less than one year</th>
<th>2013 1 to 5 years</th>
<th>2013 After 5 years</th>
<th>Total (2014)</th>
<th>Total (2013)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endowment net assets at July 1</td>
<td>$ 5,301</td>
<td>4,137</td>
<td>130</td>
<td>$ 4,733</td>
<td>4,130</td>
<td>130</td>
<td>$ 9,113</td>
<td>$ 8,026</td>
</tr>
<tr>
<td>Investment income</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net appreciation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Appropriation for expenditure</td>
<td>(488)</td>
<td>(792)</td>
<td>(450)</td>
<td>(645)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$ 9,113</td>
<td>8,026</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In 2014, a foundation notified LLS that it intended to cancel a grant commitment that was made in the previous year due to a change in the foundation’s objectives. Accordingly, LLS wrote off the balance of the contribution receivable in the amount of $3,507,000.

## 6. Deferred Revenue, Donated Services and Media

During 2013, LLS received a $20,000,000 grant with the contractual agreement to be utilized on research which is jointly identified by the grantor and LLS. At June 30, 2014 and 2013, these funds were held equally between cash and investments. Revenue under this grant is expected to be recognized over the next three years, as expenses are incurred. At June 30, 2014 and 2013, the unexpended balance of the grant of $13,700,000 and $19,500,000, respectively, are included in deferred revenue. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

<table>
<thead>
<tr>
<th>Purpose</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated services</td>
<td>$ 4,985</td>
<td>5,492</td>
</tr>
<tr>
<td>Donated media</td>
<td>6,000</td>
<td>2,258</td>
</tr>
<tr>
<td>Total</td>
<td>$10,985</td>
<td>7,750</td>
</tr>
</tbody>
</table>

## 7. Fixed Assets, Net

Fixed assets at June 30, 2014 and 2013 consist of the following (in thousands):

<table>
<thead>
<tr>
<th>Asset Category</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td>$ 1,135</td>
<td>1,043</td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>2,646</td>
<td>2,626</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>27,891</td>
<td>18,432</td>
</tr>
<tr>
<td>Total</td>
<td>$31,694</td>
<td>22,101</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(15,090)</td>
<td>(11,248)</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>$16,604</td>
<td>10,853</td>
</tr>
</tbody>
</table>
8. Retirement Plans

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated $4,214,000 and $4,173,000 for the years ended June 30, 2014 and 2013, respectively.

LLS has 457(b) deferred compensation plans (the 457 Plans) for its executive staff. The 457 Plans are nonqualified deferred compensation plans subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plans approximated $296,000 and $195,000 for the years ended June 30, 2014 and 2013, respectively. The assets and liabilities of the 457 Plans are included in investments and accounts payable and accrued expenses in the accompanying consolidated balance sheet and amounted to approximately $1,589,000 and $1,357,000 at June 30, 2014 and 2013, respectively.

9. Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through September 30, 2023 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>22,614</td>
<td>21,438</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10. Joint Costs Allocation

For the years ended June 30, 2014 and 2013, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows (in thousands):

<table>
<thead>
<tr>
<th>Joint Costs Allocation</th>
<th>2014</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$12,645</td>
<td>10,577</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,513</td>
<td>1,895</td>
</tr>
<tr>
<td>Public health education</td>
<td>8,456</td>
<td>8,966</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$22,614</td>
<td>21,438</td>
</tr>
</tbody>
</table>